Synthesis of site specific DNA methylating compounds targeting pancreatic ß-cells by NC DOCKS at The University of North Carolina Wilmington & Smith, Lacey Marie
 
 
SYNTHESIS OF SITE SPECIFIC DNA METHYLATING COMPOUNDS 
TARGETING PANCREATIC β-CELLS 
 
 
 
Lacie Marie Smith 
 
 
 
 
A Thesis Submitted to the 
University of North Carolina Wilmington in Partial Fulfillment 
Of the Requirements for the Degree of 
Master of Science 
 
 
Department of Chemistry and Biochemistry 
 
University of North Carolina Wilmington 
 
2008 
 
 
Approved by 
 
 
Advisory Committee 
 
  
    Dr. Pamela Seaton                 Dr. John Tyrell   
 
 
      Dr. Sridhar Varadarajan  
Chair 
 
 
Accepted by 
 
______________________________ 
Dean, Graduate School
This thesis has been prepared in the style and format consistent with the journal 
Journal of Organic Chemistry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ii
TABLE OF CONTENTS 
 
 
ABSTRACT.........................................................................................................................v 
 
ACKNOWLEDGEMENTS............................................................................................... vi 
 
LIST OF TABLE .............................................................................................................. vii 
 
LIST OF FIGURES ......................................................................................................... viii 
 
CHAPTER 1: INTRODUCTION........................................................................................1 
 
CHAPTER 2: BACKGROUND..........................................................................................6 
 
 2.1. Background.......................................................................................................7  
 2.1.1. DNA Structure and Reactivity .......................................................................7 
 2.1.2. Reactivity of DNA towards alkylating agents .............................................11 
 2.1.3. Biological consequences of DNA methylation............................................13 
 2.1.4. Structure and Properties of Me-lex ..............................................................14 
 2.1.5. Biological consequences of 3-MeA formation by Me-lex...........................19 
 2.1.6. DNA methylation of Streptozotocin ............................................................20 
  
 2.2. Design of molecules........................................................................................24 
 
CHAPTER 3: SYNTHESIS OF FINAL COMPOUNDS..................................................26 
 3.1. Synthetic Strategy ...........................................................................................27 
 3.2. Synthesis of cell targeting ligand....................................................................30 
 3.3. Synthesis of DNA-binding unit ......................................................................31 
 3.4. Assembly of DNA-binding unit and cell targeting unit..................................33 
CHAPTER 4: SYNTHESIS OF ANALOG COMPOUNDS.............................................47 
 4.1. Significance.....................................................................................................48 
4.2. Synthesis of stable analogs for DNA-binding experiments............................50 
 iii
 4.3. Synthesis of model compounds for cell transport studies...............................54 
CHAPTER 5: EXPERIMENTAL......................................................................................60 
 5.1. General............................................................................................................61 
 5.2. Synthesis .........................................................................................................62 
CHAPTER 6: RESULTS AND DISCUSSION...............................................................101 
REFERENCES ................................................................................................................112 
APPENDIX......................................................................................................................118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv
ABSTRACT 
 
This project involves synthesizing compounds that are capable of producing cytotoxic 
N3-methyladenine DNA adducts in pancreatic β-cells.  The compounds will consist of three 
units: 1) A cell targeting ligand, glucose, which is specific to the insulin producing pancreatic β-
cells, 2) a DNA methylating unit, Me-lex, which has been shown to selectively make N3-
methyladenine adducts, and 3) linker component which will connect the two units previously 
mentioned.  The linker portion is critical in the binding of the compounds to DNA as well as the 
ability of the compounds to be transported into the pancreatic β-cells.  Several stable analog 
compounds were synthesized to test the ability of the compounds to be transported selectively 
into pancreatic β-cells and test their binding to DNA. 
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CHAPTER 1: INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
DNA-alkylating drugs are the earliest and most common treatment for cancer 
chemotherapy.  DNA-alkylating drugs work by damaging (alkylating) DNA, thereby killing 
cells.1,2  Normal cells are able to overcome the damage caused by DNA-alkylating agents by 
going into cell cycle arrest until the damage gets repaired.  Cancer cells on the other hand divide 
rapidly and so the DNA damage in these cells does not get repaired.  Therefore cancer cells 
succumb to the treatment while normal cells do not.  But, some normal cells like hair cells, and 
cells of the gastric lining normally divide rapidly (like cancer cells) and therefore get destroyed 
as a result of this treatment.2  This is the reason why cancer patients receiving the DNA 
alkylating drugs for treatment often lose their hair and develop gastric problems.  These side 
effects result because DNA-alkylating drugs cannot be targeted only to cancer cells. 
 A more serious problem with DNA-alkylating drugs is that they can cause mutations.  
Mutations are a result of the wide spread damage inflicted on DNA.  These mutations can 
develop into a secondary cancer, which is a serious side effect for cancer chemotherapy 
patients.2,3,4  It would be very advantageous to develop new drugs that do not cause mutations 
and lead only to cell death (cytotoxicity).     
Me-lex, a molecule well described in literature5-8 is a DNA-alkylating (methylating) 
compound that produces only one kind of damage to DNA.  This particular damage leads to cell 
death and not to mutations, due to the formation of a DNA adduct known as N3-methyladenine 
(3-MeA).1  Therefore, Me-lex could be used to destroy cancer cells.  However, Me-lex has no 
cell specificity.  If Me-lex could be targeted to a particular cell (cancer cells) it would be possible 
to destroy those cells without mutations.  The ability to target a specific cell requires a cell-
specific ligand to be attached to Me-lex. 
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In order to target a cell, a cell-specific ligand has to be identified.  The cell-targeting 
ligand has to be easy to synthesize, and should be able to maintain its cell-targeting ability upon 
modification.  Streptozotocin (STZ), Figure 1, is a potent DNA-alkylating drug that targets the 
insulin producing pancreatic β-cells because of its specific transport through the GLUT-2 
glucose transporter.9-10  The glucose unit in STZ is believed to be responsible for its selective 
transport.  The high levels of the GLUT-2 transporter on the surface of  pancreatic β-cells makes 
STZ very toxic to these cells.11  Streptozotocin was developed to study diabetes in mice by 
analyzing the sequence of events in pancreatic β-cell destruction (type-1 diabetes).12-15  There is 
evidence that large molecules, such as porphoryin rings connected to glucose can be transported 
by glucose transporters into the pancreatic β-cell.16  Therefore it is likely that Me-lex attached to 
glucose would be transported into the pancreatic β-cells too. 
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Figure 1.1: Structure of Streptozotocin (STZ). 
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The ability to target Me-lex to pancreatic β-cells by attaching it to glucose will provide 
proof that this strategy can be used to destroy unwanted cells by targeting Me-lex to those cells.  
An added advantage of targeting Me-lex to the pancreatic β-cells is that it could be used as a new 
model for studying type-1 diabetes.11-13  STZ is currently used to induce diabetes in animals.  
However, due to the extensive DNA damage, and consequent mutations caused by STZ, animals 
treated with STZ develop tumors.  DNA damage caused by Me-lex would not cause such tumors. 
The goal of this thesis is to synthesize new compounds that incorporate the pancreatic β-
cells-targeting abilities of glucose and the selective DNA-methylating abilities of Me-lex into a 
single molecule.  Such molecules would have the ability to selectively deliver cytotoxic damage 
only to pancreatic β-cells. 
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CHAPTER 2: BACKGROUND 
 
 
 
 
 
 
 
 
 
 
 
2.1. Background: 
The molecules designed and synthesized for this project should be able to target the 
pancreatic β-cells via the GLUT-2 cells, bind to the minor groove of DNA at A/T rich regions 
within those cells, and methylate the N3 position of adenine on DNA.  Therefore designing 
compounds that have these three properties requires a good understanding of DNA structure and 
reactivity, and of the characteristics that enable transport through the GLUT-2 glucose 
transporter.  
 
2.1.1. DNA Structure and Reactivity: 
DNA (deoxyribose nucleic acid) is composed of two strands held together through 
hydrogen bonding.  Each strand has a phosphate, sugar, and base.  The phosphate and sugar form 
the backbone.  The bases are adenine (A), thymine (T), guanine (G) and cytosine (C).  Hydrogen 
bonding between the bases brings the two complementary strands together to form a double 
helix; A and T are paired together by two hydrogen bonds and G and C are paired together by 
three hydrogen bonds.  Figure 2.1 shows the structure of B-DNA.  This double helix is a right-
handed spiral which results in two distinct grooves, the minor groove and the major groove.  The 
minor groove is deep and narrow and therefore sites within the minor groove are more difficult 
to access.  The major groove is wide and shallow making the sites within the major groove easier 
to access.  Typically, most proteins and enzymes interact with DNA in the major groove. 
 
 
 
 
 7
 
 
Figure 2.1: Structure of B-DNA. 
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Figure 2.2 represents the hydrogen bonding interactions between the G/C base pairs and 
the A/T base pairs.  There are sites on each base pair that lie in the major groove and sites that lie 
in the minor groove as shown.  The most accessible sites in the major groove at a G/C base pair 
are the N7 of guanine, O6 of guanine, and N4 of cytosine.  The sites on the G/C base pair that are 
in the minor groove and usually difficult to access are the N3 of guanine, N2 of guanine, and O2 
of cytosine.  The sites on the A/T base pair that are easily accessible in the major groove are the 
N7 of adenine, O4 of thymine, and N6 of adenine.  The sites on the A/T base pair that are less 
accessible are the minor groove sites O2 of thymine and N3 of adenine.  The site of particular 
interest for this project is the N3 position of adenine located, within the minor groove. 
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Figure 2.2: Hydrogen bonding interactions between the DNA base pairs. 
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2.1.2. Reactivity of DNA towards alkylating agents: 
There are many sites that can be alkylated on DNA.  Some of these sites lie within the 
minor groove, some lie within the major groove, and some are located on the sugar-phosphate 
backbone.  In Figure 2.3, the arrows represent all the sites that can be alkylated by alkylating 
agents.1-2, 7, 17-18  Alkylation at some of these sites can lead to the death of a cell.  Alkylation at 
other sites can lead to mutations, which is usually an undesired effect.  There are some sites at 
which alkylation has no consequence and there are some sites at where alkylation leads to both 
cell death mutations.  
In the major groove, methylation at the N7 of guanine is benign; however, 
methylation/alkylation at the O6 of guanine is known to cause both mutations and cell death.1-2, 7, 
17-19   A general trend appears to be that alkylation at sites involved in the hydrogen bonding of 
the base pairs results in mutations while alkylation at other sites usually does not lead to 
mutations.  There is evidence that methylation at the N3 position of adenine in the minor groove 
causes only cell death and not mutations. 7, 17, 19-2  Therefore the N3 position of adenine would be 
an attractive site on DNA to methylate in order to bring about cell death. 
There are multiple nucleophilic sites on DNA that can react with alkylating agents.  The 
most nucleophilic and accessible site on DNA and therefore the most commonly alkylated site is 
the N7 of guanine in the major groove.  Alkylation in the minor groove is less uncommon do to 
the sites being less accessible.  Alkylation at each of these sites can lead to different biological 
consequences. 
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Figure 2.3: Methylation/alkylation sites in the major and minor groove of DNA are 
indicated by arrows. 
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2.1.3. Biological consequences of DNA methylation: 
The biological consequences of DNA alkylation depends upon the site of alkylation and 
the alkylating unit.  Methylation at the N7 of guanine in the major groove appears to have no 
biological consequence.1, 7, 17-18  The O6 of guanine, also in the major groove, and involved in 
hydrogen bonding interactions with cytosine is another commonly methylated site.  Methylation 
at this site can result in both mutations and cell-toxicity.1, 7, 17-18      
Methylation at other sites that can result in mutations are the N2 of guanine, the O2 and O4 
of thymine, and O2 of cytosine.1, 7, 17  However, methylation at the N3 site of adenine, in the 
minor groove, has shown to result in cytotoxicity, without leading to mutations.7, 17, 19-21  Thus 
compounds that can exclusively make 3-MeA adducts can be used to kill cells without any risk 
of mutations.   
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2.1.4. Structure and Properties of Me-lex: 
Me-lex is known to bind to the minor groove of DNA at A/T rich regions and methylate 
the N3 position of adenine. 5, 7-8, 20-22  Me-lex (Figure 2.4a) is a crescent shaped, neutral 
compound that consists of an N-methylpyrrolecarboxamide dipeptide (lex), with a propyl group 
at one end (C-terminus), and a reactive methyl sulfonate at the other end (N-terminus).  Me-lex 
binds selectively to A/T rich regions in the minor groove due to specific interactions with bases 
in these regions.  The crescent shape allows Me-lex to fit perfectly within the minor groove as 
illustrated in Figure 2.4b.  Me-lex establishes favorable hydrogen bonding interactions between 
the N-H of the amide hydrogens of Me-lex and the N3 position of adenine and the O2 of thymine 
in these regions (Figure 2.5a).  Me-lex also establishes numerous van der Waal contacts that aid 
in its binding with DNA.  Typically, Me-lex requires three to four A/T base pairs in a sequence, 
without any interfering guanine bases for it to bind to these regions.  The reason it does not bind 
to the G/C base pair regions in the minor groove is because the exocyclic amine on the C2 
position of guanine is located in the minor groove and causes steric hindrance with the  
C-H on the pyrrole of Me-lex (Figure 2.5b).   
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   a      b 
Figure 2.4: a) Structure of Me-lex. b) Computational model showing Me-lex bound within the 
minor groove of DNA. 
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Figure 2.5: a) Me-lex’s hydrogen bonding interactions with adenine in the minor groove. 
 b) Steric hindrance between Me-lex and guanine in the minor groove. 
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When Me-lex binds selectively to the A/T rich regions in the minor groove; the molecule 
places the reactive methyl sulfonate group at these A/T rich regions as shown in Figure 2.6.  In 
these regions the N3 position of adenine is the most nucleophilic site.  Therefore, Me-lex 
exclusively methylates DNA at this site; resulting in > 95 % of the methylated DNA-adducts 
formed by Me-lex being 3-MeA adducts.5-8  Once the reactive methyl group is transferred to the 
N3 position of adenine, the resulting sulfonate anion with a negative charge, gets eliminated 
from DNA due to electrostatic repulsion with the negatively charged phosphate backbone of 
DNA. 7, 39  Thus, this molecule functions as an efficient delivery agent for the methyl group and 
does not have any further biological consequences of its own by staying associated with the 
DNA.   
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Figure 2.6: DNA-methylation at A/T rich regions in the minor groove of DNA. 
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2.1.5. Biological consequences of 3-MeA formation by Me-lex: 
The 3-MeA adducts formed by Me-lex have been shown to be cytotoxic in yeast, E. coli, 
and mammalian cells.19-23  It has also been shown that the extent of cell death correlates to the 
levels of 3-MeA adducts formed. 19-23  The 3-MeA adducts formed by Me-lex have also been 
shown to be non-mutagenic.  While Me-lex has attractive properties in terms of cell toxicity, its 
development into a useful drug is limited by the fact that it has no cell specificity.  The ability to 
deliver Me-lex to a particular cell would aid in the development of drugs for cancer 
chemotherapy.  The goal of this project is to develop new compounds which can use the 
selective DNA-methylating property of Me-lex and deliver it to a cell of interest. 
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2.1.6. DNA methylation of Streptozotocin: 
Streptozotocin (STZ, Figure 2.7) is a potent DNA-methylating agent that is known to 
methylate DNA at multiple sites and has been shown to have selective pancreatic β-cell 
toxicity.9-11, 13-15  STZ has a glucose unit to which it is attached to a N-methyl-N-nitrosurea unit 
The nitrosurea unit methylates the DNA and it is believed that the glucose unit is responsible for 
the ability of STZ to target pancreatic β-cells due to selective transport through the low affinity 
glucose transporter, GLUT-2, that is present on the surface of the pancreatic β-cells.24, 25, 27   
Methylation by STZ occurs at multiple sites on DNA.  The sites that can be methylated 
by STZ include: N7 of guanine, O6 of guanine, N7 of adenine, and N3 of adenine.9  Over 70 % of 
the DNA adducts formed by STZ is N7-methylguanine, which is a begin adduct. 1,7, 9, 17, 18  STZ 
also forms the O6 –methylguanine adduct in the major groove, which is known to cause both 
mutations and cell death.1, 7, 17, 18  The formation of O6-MeG adduct by STZ is believed to result 
in tumors.  It is likely that STZ kills pancreatic β-cells due to the formation of 3-MeA adducts 
and O6- MeG.7, 14
STZ has been used for studying type-1 diabetes by killing pancreatic β-cells in rodent 
(mice) models.12, 14  However, in these cases the study of type-1 diabetes is complicated by the 
fact that STZ causes extensive damage to DNA at multiple sites resulting in mutations which 
cause tumors. 
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Figure 2.7: Structure of Streptozotocin (STZ). 
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The glucose unit of STZ is responsible for targeting it specifically to pancreatic β-cells.  
The glucose unit has also been known to target other molecules to pancreatic β-cells through the 
GLUT-2 glucose transporter.  Figure 2.8a shows another small compound containing the glucose 
unit that has been known to selectively target the pancreatic β-cells.  There is a recent patent16 
that describes porphoryin-glucose conjugates in photodynamic therapy for cancer (Figure 2.8b).  
Their uptake in these cancer cells was believed to involve glucose transporters on the surface of 
the cells.  All the evidence indicates that it should be possible to deliver a compound like Me-lex 
to the pancreatic β-cells by attaching glucose to Me-lex at an appropriate location. 
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Figure 2.8: a) Chlorozotocin is a small molecule that can be transported by glucose transporters. 
b) Structure of Pyro-2DG. 
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2.2. Design of molecules: 
 The goal of this project is to develop new compounds which can produce 3-MeA adducts 
selectively in pancreatic β-cells.  New molecules have been designed (Figure 2.9) that include 
glucose as the cell-targeting component, and Me-lex as the DNA-methylating component.  The 
design of the new molecules must be such that the glucose unit maintains its ability to be 
transported by the GLUT-2 glucose transporter, and that the bis-pyrrole unit maintains its ability 
to selectively bind to the minor groove of DNA at A/T rich regions, and methylate the N3 
position of adenine.  As seen in the figure 2.9, the new compounds have the glucose unit 
connected to the C-terminus of the DNA-binding unit (bis-pyrrole dipeptide) while the DNA-
methylating unit is connected to the N-terminus at the other end.   
The bis-pyrrole and the glucose unit will be connected by a linker.  The linker is the only 
part of the molecule that can be varied in this design.  The linker has to be such that it optimizes 
the DNA-methylating and cell targeting functions of the molecules.  The linker can also be 
modified, if necessary, to improve DNA-binding of the compounds, as well as increase water 
solubility.  For this project the linker was varied only in length (R = (CH2)n were n = 1, 2, 3).  
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Figure 2.9: Design of molecules for this project. 
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CHAPTER 3: SYNTHESIS OF FINAL COMPOUNDS 
 
 
 
 
 
 
 
 
 
 
 
3.1. Synthetic Strategy: 
The synthesis of compounds that can specifically target pancreatic β-cells, selectively 
bind to the minor groove of DNA at A/T rich regions within those cells, and methylate adenines 
within those regions, can be divided into four components.  These components include a cell-
targeting unit (glucose), a DNA-binding unit (bis-pyrrole dipeptide), a linker unit (R), and a 
DNA-methylating unit (methyl sulfonate).  Each of these components was synthesized/obtained 
separately and functionalized appropriately so that they could be assembled together to form the 
desired compounds described below.   
Figure 3.1 shows the overall synthetic strategy for assembling the four components.  
DNA-binding unit consists of a bis-pyrrole dipeptide to which other components will be added 
on either side to form amide linkages.   Therefore the DNA-binding unit was constructed with an 
amine at one end (N-terminus) of the molecule and a carboxylic acid at the other end (C-
terminus).  Linker units were obtained commercially as amino esters.  The amines of the linkers 
were connected to the C-terminus of the bis-pyrrole dipeptide to form an amide linkage.  
Subsequently, the ester at the other end of the linker was hydrolyzed into a carboxylic acid and 
condensed with the amine of cell-targeting unit.  The N-terminus of the bis-pyrrole was then 
derivatized and converted into the reactive methyl sulfonate.  
Certain considerations were taken into account while constructing and assembling these 
components.  The DNA-methylating methyl sulfonate is a reactive group and therefore has to be 
added at the last step in the synthesis.  The cell-targeting unit (glucose) has several hydroxyl 
(OH) groups that have to be masked so that they do not interfere with the various reactions and 
manipulations that are required for synthesizing and assembling the final compounds.  The 
 27
hydroxyl groups would be regenerated just before the introduction of the reactive methyl 
sulfonate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28
 
 
Figure 3.1: Synthetic strategy. 
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3.2. Synthesis of cell targeting ligand: 
The cell-targeting ligand, glucose, has four nucleophilic OH groups and one nucleophilic 
amine group.  The amine of glucose has to be condensed with the carboxylic acid at the C-
terminus of the DNA-binding unit.  In order to prevent interference from the OH groups during 
the condensation they have be protected first.  Two different protecting groups were considered.  
Protection with acetyl groups can be easily accomplished in high yields using acetic anhydride, 
and the resulting compounds are easily purified and characterized.  Subsequently, deprotection 
can be achieved using basic conditions, but it is also possible to deprotect the acetyl groups using 
strong acid.  Therefore strongly acidic or basic conditions used during chemical manipulations 
may result in premature deprotection of the OH groups.  Protection with benzyl groups resulted 
in lower yields than the acetyl protection, and resulted in compounds that are more difficult to 
characterize by NMR due to the overwhelming number of aromatic hydrogens in the spectrum.  
However, the benzyl groups are stable to acidic and basic conditions, can be removed in a single 
hydrogentation step, and the only byproduct formed upon deprotection is toluene which can be 
easily removed by rotary evaportation.   
The protection of oxygens on glucose by both protecting groups is well described in 
literature, 28, 35  and outlined in Schemes 3.2.1 and 3.2.2. In both cases the synthesis begins with 
commercially available D(+) glucosamine hydrochloride.  The amine is first masked as the imine 
(10) and then the OH groups are protected with either the acetyl (11) or benzyl groups (40).  
Subsequently the imine is converted back to the amine (12, 41).  The protected glucosamines 12 
and 41 were synthesized in large quantities and stored as their hydrochloride salts until required. 
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3.3 Synthesis of DNA-binding unit: 
The DNA-binding unit was synthesized as described in literature with certain 
modifications.20. 34  This modified procedure has been optimized in our laboratory earlier.  The 
synthetic sequence that was used is outlined in Scheme 3.3.1. 
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Scheme 3.3.1 
 
Commercially available N-methylpyrrole was converted into the trichloroacetyl 
compound 1 and then nitrated to give 2, which was then reacted with the amines of various 
linkers to give compound 3 in excellent yields.  The nitro compound 3 was reduced to an amine 
and condensed with 1 to afford the bis-pyrrole unit 5 in excellent yields.  The nitro group on 
compound 5 was then reduced to the amine and condensed with acryloyl chloride to afford 
alkene 14.  Compound 14 now contains the bis-pyrrole triamide core required for selective 
recognition of the minor groove of DNA at A/T rich regions, and also incorporates the linker unit 
that will connect this molecule to the cell targeting ligand.  The ester on compound 14 was 
hydrolyzed into the carboxylic acid in nearly quantitative yields for subsequent condensation 
with the amine on the targeting ligand to give 15 in good yields.  The overall yield of 15 starting 
from N-methyl pyrrole was 34 %.   
 32
3.4. Assembly of DNA-binding unit and cell targeting unit: 
 The DNA-binding unit in the form of compound 15 (Figure 3.2a), has an alkene at the N-
terminus that can be converted into the methyl sulfonate, and has a carboxylic acid at the C-
terminus which can be combined with the amines of 12 and 41 (Figure 3.2 b & c, respectively) 
by forming amide linkages.   
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Figure 3.2: a) DNA-recognition unit 15 functionalized as an alkene-carboxylic acid. b) Acetyl 
protected glucosamine hydrochloride, 12. c) Benzyl protected glucosamine hydrochloride, 41. 
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The DNA-binding unit 15 with varying linker length (R = (CH2)n were n = 1, 2, 3) was 
condensed with compound 12 to yield 16 as shown in Scheme 3.4.1.   
 
 Scheme 3.4.1 
This condensation was achieved using standard carbodimide coupling methods.  The mechanism 
for this reaction using EDCI as the carbodiimide, is illustrated in Scheme 3.4.2a.  EDCI is a 
water soluble carbodiimide that gets protonated at the imide nitrogens by the carboxylic acid 15 
and then reacts with the carboxylat anion to form the activated O-acylurea intermediate.  This 
activated carboxylic acid can react to form the desired product.  However, this O-acylisourea 
intermediate can undergo rearrangement to form an unreactive N-acylurea which cannot react 
with an amine.36   
 
Scheme 3.4.2a 
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Therefore, HOBT is often used in these reactions to trap the intermediate, minimize the side 
reaction, and increase yields.36  The intermediate formed by HOBT can react with an amine to 
form the amide product and regenerate HOBT as illustrated in scheme 3.4.2b.  It has been 
reported in literature and reaction conditions that the use of CuCl2 and DMAP in these reactions 
can lower the formation of the N-acylurea intermediate and increase product yields.37  Therefore 
using a combination of these reagents to synthesize 16 resulted in yields greater than 85 %.  
 
Scheme 3.4.2b 
The alkene, 16, now has to be converted into the sulfonic acid.  This conversion was 
attempted using sodium bisulfite at pH 8 as shown in scheme 3.4.3.   
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The reaction was monitored by TLC for the disappearance of the alkene.  Once TLC indicated 
complete conversion of the alkene (only a baseline spot was observed) the solution was acidified 
with HCl and the solvent removed by rotary evaporation.  However, NMR analysis of the crude 
product indicated that while the sulfonic acid had been successfully formed (indicated by the 
characteristic shifts of the two methylenes next to the sulfonic acid), the glucose unit had 
undergone some transformation, possibly deprotection, as indicated by the presence of multiple 
acetyl peaks integrating to less than what was expected, and by the presence of a number of 
glucose ring hydrogens.  All attempts to isolate and characterize individual components from this 
mixture was unsuccessful.  
If the glucose unit was indeed getting deprotected, it would not be a problem since the 
next step planned after the formation of the sulfonic acid was the deprotection of the glucose.  In 
fact, it would be advantageous to accomplish both the conversion of the alkene into the sulfonic 
acid and deprotection of the glucose in a single step.  However, it was unclear whether the 
deprotection was taking place during the reaction (since basic conditions are known to cause the 
deprotection) or during the subsequent acidification.   
In order to address these questions and to identify the optimum conditions under which 
deprotection of the glucose unit could be achieved, investigations were carried out using the 
model compound shown in Figure 3.3.  The use of the model compound was necessary to 
investigate the effects of various conditions on the glucose unit without any interference from 
other functional groups (present on 16) and also because this model compound was more easily 
obtained than compound 16.   
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Figure 3.3: Structure of model compound. 
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Model compound 26 was synthesized as shown in Scheme 3.4.4 and the subjected to the 
same reaction conditions that were used for the conversion of compound 16 to the sulfonic acid 
(see Scheme 3.4.3).  Refluxing 26 under these mildly basic conditions for prolonged periods  
 
Scheme 3.4.4 
 
resulted in no alteration to compound 26, as verified by TLC and NMR.  However, when 
compound 26 was subjected to acidic conditions (concentrated HCl) the glucose unit was clearly 
affected, as evidence by numerous peaks in the H1 NMR spectrum in the regions where the 
acetyl hydrogens and the glucose ring hydrogens show up.  However, acidification with 1M HCl 
did not affect the protected glucose unit.   
Model compound 26 was also used to determine the optimum conditions for the 
deprotection reaction.  The use of several different conditions are reported in literature for this 
purpose.40-43  Some of these conditions were investigated with compound 26.  The investigated 
conditions and the observed results are shown in Table 3.1.  
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Table 3.1: Various reaction conditions used for removal of acetyl groups from glucose. 
 
Reagents Temperature(0 oC) 
Time 
 
Acidification 
with Results 
7N NH3/MeOH 25 3 hrs. - Partial Deprotection 
K2CO3/H2O 25 4 hrs. 1M HCl Partial Deprotection 
6M HCl 85 1 hr - Partial Deprotection 
1M HCl 25 24 hrs. - No Deprotection 
NaOCH3/MeOH  25 3 hrs. Dowex 50 WX-4 Complete Deprotection
NaOCH3/MeOH  -10 15 mins. Dowex 50 WX-4 Complete Deprotection
NaOCH3/MeOH -78 1 hour Dowex 50  WX-4 Partial Deprotection 
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The removal of the acetyl groups was monitored by NMR.  Based upon these studies, the 
use of NaOCH3/MeOH at -10 oC, followed by acidification with Dowex 50 WX-4 resin was 
adopted as the most suitable method for deprotection reactions as shown in Scheme 3.4.5.  
However, the NaOCH3 used had to be freshly prepared; the use of NaOCH3 prepared earlier 
resulted in incomplete deprotection.  
 
Scheme 3.4.5 
While complete deprotection was achieved using these conditions as indicated by the 
complete disappearance of the acetyl CH3 peaks in the NMR spectrum, two sets of peaks were 
observered for the glucose hydrogens.  Based upon literature evidence,44 and upon further NMR 
experiments (HMQC and COSY), it was determined that two anomeric forms of the glucose unit 
were present as shown in Figure 3.4.   
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Figure 3.4: a) Anomeric forms of 27. b) 1H NMR of both anomers in d6-DMSO. 
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Based upon these studies with the model 26, compound 16 was first treated with NaHSO3 
at pH 8 in order to convert the alkene into the sulfonate, but the reaction was not acidified.  This 
reaction requires the presence of oxygen for efficient conversion since it is believe to proceed 
through a radical mechanism.26, 38 as shown in Scheme 3.4.6.  The crude product obtained from 
the reaction was examined by NMR to confirm the disappearance of the alkene and the presence 
of the acetyl groups.  Acidification of this product with 1M HCl and Dowex 50 WX-4 resin is 
currently being investigated.  
 
 
 
Scheme 3.4.6 
 
 
  
Since the conversion of alkene 16 to the desired sulfonic acid has proved to be difficult 
due to the instability of the acetyl protecting groups on the glucose to the reaction conditions, the 
acetyl protected glucose unit of 16 was replaced with benzyl protected glucose, since the benzyl 
groups is stable to both acidic and basic conditions.  Thus, compound 41 was condensed with 
15b using carbodiimide coupling as shown in Scheme 3.4.7 to yield 42.  
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Scheme 3.4.7 
Compound 42 was converted into the sulfonate using NaHSO3 at pH 8 as shown in 
Scheme 3.4.8.  Protonation of the sulfonate with concentrated HCl successfully produced the 
sulfonic acid while leaving the benzyl groups intact.  Compound 43 was purified by flash column 
chromatography. 
Scheme 3.4.8 
  
An attempts to remove the benzyl groups on the glucose of compound 43 are currently in 
progress.  An initial attempt using H2  (75 psi) and 10 % Pd on carbon as a catalyst was 
unsuccessful.  However, evidence in literature indicates that other researchers have had similar 
problems in the removal of the benzyl groups using 10 % Pd/C.  It has been reported that the use 
of palladium black as a catalyst will result in quantitative yields for debenzylation.41, 43  The use 
of this new catalyst is currently being explored in the laboratory.   
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Once the benzyl groups can be successfully removed the next step is the methylation of 
the sulfonic acid to the methyl sulfonate as shown in Scheme 3.4.9.  This methylation will be 
attempted using either trimethyl ortho formate or methyl-p-tolytriazine as the methylating agent.  
It is known that these methylating agents can methylate sulfonic acids of similar compounds, and 
it has been verified that they do not methylate the hydroxyl groups on the glucose.  Once the 
sulfonic acid is methylated the compounds will be used in experiments with DNA to characterize 
its ability to methylate DNA. 
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Scheme 3.4.9
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CHAPTER 4: SYNTHESIS OF STABLE ANALOG COMPOUNDS 
 
 
 
 
 
 
 
 
 
 
 
4.1. Significance: 
The desired compounds for this project have to achieve two main functions in order to 
succeed in selectively destroying pancreatic β-cells.  They should be efficiently transported by 
the GLUT-2 glucose transporter on the pancreatic β-cells, and they should exhibit DNA-binding 
properties comparable to Me-lex (and consequently similar DNA-methylation characteristics).  
Failure to perform either of these two functions efficiently will render the molecules incapable of 
destroying the pancreatic β-cells. 
The linker is the component that is being varied in the design of the compounds in order 
to optimize both DNA-binding and transport via the GLUT-2 transporter.  However the features 
of the linker that favor efficient DNA-binding may not be the same features that favor efficient 
transport through the transporter.  Therefore, it is essential to determine the features influencing 
each of the two functions independently.  
 Since the target compounds are reactive methyl sulfonates that can react with various 
nucleophiles, stable analogs have to be synthesized for use in experiments to determine DNA-
binding and cell transport properties.  Therefore, for the DNA-binding studies model compounds 
were designed in which the reactive methyl sulfonate (Figure 4.1a) was replaced by a stable 
methyl sulfone (Figure 4.1b).  In order to investigate cell transport, model compounds were 
designed in which the reactive methyl sulfonate was replaced by a fluorescent tag, NBD or 
coumarin (Figure 4.1c and d, respectively). 
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Figure 4.1: Compounds designed for a) DNA-methylation studies. b) DNA-binding studies.  
c) Cell transport studies with NBD d) Cell transport studies with coumarin. 
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4.2. Synthesis of stable analogs for DNA-binding experiments: 
A general synthetic route was first designed (scheme 4.2.1) that would result in a 
molecule having the methyl sulfone unit attached to the bis-pyrrole triamide with the linker 
attached at the other end and functionalized as a carboxylic acid.  This molecule could then be 
attached to various targeting ligands for different projects.  
 
 
Scheme 4.2.1 
 
Compound 5b that was synthesized earlier (Scheme 3.3.1) was used as the starting point for 
determining the feasibility of this synthetic scheme.  As shown in Scheme 4.2.2a the nitro group 
on compound 5b was reduced to an amine and condensed with 3-(methylsulfonyl)propanoic acid 
using carbodiimide coupling, to give compound 25b.  The ethyl ester of compound 25b was then 
hydrolyzed using basic conditions.  Hydrolysis of the ethyl ester was achieved, but the product 
that was isolated was the alkene 15b and not the desired product.  Presumably, the basic 
conditions resulted in an elimination reaction as shown in Scheme 4.2.2b. 
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Scheme 4.2.2a 
 
 
Scheme 4.2.2b 
 
 Various reaction conditions were explored such as altering temperature, solvents, reaction 
time, and the base used, but none of them resulted in the hydrolysis of the ester while leaving the 
sulfone intact.  Therefore, an alternative synthetic procedure was adopted where in the ester was 
hydrolyzed and attached to the cell targeting ligand before the methyl sulfone was introduced.  
This alternative synthetic procedure is shown in Scheme 4.2.3.  The ethyl ester of compound 5 
(synthesized earlier, see Scheme 3.1.1) was converted to the carboxylic acid using base 
hydrolysis to give quantitative yields of 9.  Compound 9 was then condensed with the targeting 
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ligand 12 using carbodiimide coupling to form compound 13.  This nitro group on compound 13 
was reduced to the amine and condensed with 3-(methylsulfonyl)propanoyl chloride to give 18. 
 
Scheme 4.2.3 
 The acetyl groups of compound 18b were removed using freshly prepared 
NaOCH3/MeOH at -10 oC in anhydrous THF.  Dowex 50 WX-4 resin was subsequently used to 
acidify the reaction mixture.  The optimization of this procedure has been described earlier in 
Section 3.4.  This procedure resulted in the formation of compound 44b the desired product for 
DNA-binding experiments in quantitative yields as shown Scheme 4.2.4.  The synthesis and 
isolation of compounds 44a and c are currently in progress.  Compound 44b is soluble in water, 
which makes it convenient for binding studies which are conducted in an aqueous medium. 
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Scheme 4.2.4 
The methylsulfone compounds, with the targeting ligand glucose attached will be used to 
determine the strength of their binding interactions with the A/T rich binding site on DNA.  The 
strength of their binding will be compared to the strength of binding of the methyl sulfone 
corresponding to Me-lex (compound 17, Scheme 4.2.5).  If the DNA-binding of the new 
compounds is comparable to that of compound 17, then it is likely that the DNA-methylating 
characteristics of the newly synthesized methyl sulfonates with the glucose ligand attached will 
be similar to that of Me-lex.  Compound 17 was synthesized as shown in Scheme 4.2.5 based on 
published procedures.23  
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4.3. Synthesis of model compounds cell transport studies: 
 Model compounds containing fluorophores will be used to determine if the glucose unit 
is capable of transporting the DNA-binding bis-pyrrole unit into cells that contain the GLUT-2 
transports.  A comparison of the transport of fluorescently tagged compounds into cells 
expressing the transporter and cells lacking the transporter (available with collaborators) will 
provide the desired information.  Therefore, the synthesis of compounds containing the 
fluorophores NBD or coumarin was attempted (Figure 4.2).  
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Figure 4.2:  Compounds for cell transport studies a) NBD. b) Coumarin. 
 
 
 
 
 
 
 
 
 55
As shown in Scheme 4.3.1 commercially available NBD-Cl (4-chloro-7-nitro-2,1,3-
benzoxadiazole) was condensed with β-alanine ethyl ester hydrochloride using triethylamine 
(TEA) to yield 33. 
 
Scheme 4.3.1 
However, the conversion of ester 33 into the carboxylic acid using base hydrolysis was 
unsuccessful.  The proton NMR spectrum after the hydrolysis reaction indicated the presence of 
three aromatic hydrogens.  Therefore an alternative procedure, described in literature,29 was used 
to make compound 19 by reacting β-alanine with NBD-Cl as shown in Scheme 4.3.2. 
N
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N N
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O
O
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19, 90 %  
Scheme 4.3.2 
Compound 19 was then condensed with 13 using carbodiimide coupling to give 21 as 
shown in Scheme 4.3.3. 
 56
 
Scheme 4.3.3 
The final step in this synthesis is deacetylation of 21, which is yet to be accomplished.  The 
acetyl groups will be removed using NaOCH3 as outlined in Scheme 4.3.4. 
   
 
Scheme 4.3.4 
Once compound 21 is successfully deacetylated these compounds will be tested by 
collaborators to determine if they are transported by the GLUT-2 glucose transporter. 
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For the preparation of the model compound containing coumarin as the flororescent tag 
(see Figure 4.2b).  Compound 15b (synthesized earlier scheme 4.2.3) was reduced to an amine 
and condensed with a N-Boc-β-Alanine to form compound 29 as shown in Scheme 4.3.5.   
 
Scheme 4.3.5 
The Boc protecting group on 29 must be removed with strong acid in order to condense it with 
coumarin-3-carboxylic acid.  Tetrafluoroacetic acid (TFA) was used to remove the Boc group, 
however, it also caused partial deprotection of the acetyl groups as determined by NMR.  
Therefore an alternative approach was adopted in which β-alanine ethyl ester hydrochloride was 
first attached coumarin-3-carboxylic acid as shown in Scheme 4.3.6. 
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Scheme 4.3.6 
Commercially available β-alanine ethyl ester hydrochloride was condensed with the 
coumarin compound using carbodiimide coupling to yield 31.  The ester of 31 was then 
hydrolyzed by using base hydrolysis at room temperature to give the carboxylic acid 32.  The 
condensation of 32 with compound 15 is currently ongoing in the laboratory.   
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CHAPTER 5: EXPERIMENTAL 
 
 
 
 
 
 
 
 
 
 
5.1. General: 
 All solvents and reagents were purchased with the highest grade available from VWR 
International (West Chester, Pennsylvania) or Sigma-Aldrich (Atlanta, Georgia).  Flash 
chromatography was performed with silica gel 60 Geduran® (40-63 µm mesh, Merck).  TLC was 
performed on aluminum plates coated with silica gel 60 (F254, Merck) that had a fluorescence 
indicator and were detected by UV visualization.  All rotary evaporations were carried out using 
a Buchi R-3000 or a Buchi R-114 rotary evaporator equipped with a Brinkman model B-16 
vacuum aspirator.  Hydrogenations were performed using a Parr Hydrogenation Apparatus in a 
500 mL Parr jar.  Melting points were determined using a Mel-Temp II. 
 All anhydrous reactions were carried out under positive pressure argon or nitrogen.  
Glassware for anhydrous reactions were dried overnight in the oven set at 150 oC, assembled 
while still hot, and cooled to room temperature under argon or nitrogen.  Solvent and reagents for 
anhydrous reactions were purchased in sure-seal capped bottles and transferred to reactions by 
oven dried needles and glass syringes. 
 All 1H-NMR and 13C-NMR spectra were obtained with a Bruker 400MHz NMR 
spectrometer, using deuterated D6-DMSO, deuterated chloroform, or deuterated methanol as the 
solvent.  The deuterated D6-DMSO was obtained in sealed ampoules and 100 mL bottles from 
Sigma-Aldrich.  The deuterated chloroform was obtained from Alfa Aesar.  The deuterated 
methanol was obtained from Sigma-Aldrich.  The spectra were reported in ppm and referenced 
to deuterated D6-DMSO (2.49 ppm for 1H, 39.5 ppm for 13C) or referenced to chloroform (7.26 
ppm for 1H, 77 ppm for 13C).  The NMR tubes were 5 mm Pyrex glass obtained from Wilmad-
LabGlass, Buena, New Jersey.   
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5.2. Synthesis: 
 2,2,2-Trichloro-1-(1-methyl-1H-pyrrol-2-yl)ethanone (1).  Trichloro acetyl chloride 
(50 mL) was added to 250 mL of dry dichloromethane in a 1000 mL flask flushed with argon.  In 
a dropping funnel, N-methyl pyrrole (50 mL) was dissolved 100 mL of dry dichloromethane.  
This mixture was then added drop wise to the trichloro acetyl chloride and stirred overnight.  To 
quench the reaction a solution of potassium carbonate (32 g in 250 mL of DI water) was added to 
the empty drop funnel and added over a two hour period.  The mixture was then extracted with 
DI water (2 x 300 mL) and dichloromethane (1 x 300mL).  The organic layer was dried over 
MgSO4, filtered, and the filtrate concentrated under rotary evaporation to produce an oily 
substance.  A pure seed was added and the flask placed under vacuum until dry to yield a dark 
brown solid 1 (80.35 g, 80%): mp 51-57 oC.  TLC (1:1 EtOAc/Hexane) Rf = 0.56.  1H NMR data 
(CDCl3): δ 7.45 (dd, J = 1.6, 6 Hz, 1H), 6.94 (s, 1H), 6.17 (dd, J = 2.4, 6 Hz), 3.93 (s, 3H).  13C 
NMR data: δ 172.34, 135.80, 124.19, 121.18, 109.60, 96.55, 38.45.  
2,2,2-Trichloro-1-(1-methyl-4-nitro-1H-pyrrol-2-yl)ethanone (2).  Compound 1 (25 g) 
was dissolved in acetic anhydride (175 mL) in a 500 mL round bottom flask and cooled to -40 oC 
in a dry ice/acetone bath.  After maintaining the temperature for 20 minutes fuming nitric acid 
(12.3 mL) was added slowly in a addition funnel for one hour with constant stirring.  Stirring 
continued for an additional 45 minutes while keeping the temperature at -40 oC.  The solution 
was then allowed to warm to room temperature over two hours.  The flask was then immersed in 
an ice water bath as cold DI water (101 mL) was added slowly in portions over one hour.  This 
mixture was then allowed to stir overnight at which point a brown-orange precipitate was formed 
and filtered under  vacuum until dryness to give 2 (23.48 g, 80%): mp 112-120oC.  TLC (1:1 
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EtOAc/Hexane) Rf = 0.84.  1H NMR data (CDCl3): δ 7.94 (d, J = 1.6 Hz, 1H), 7.75 (d, J = 1.6 
Hz, 4.05 (s, 3H).  13C NMR data: δ 173.31, 134.74, 133.08, 121.10, 116.81, 95.03,  
Ethyl 2-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)acetate (3a).  The nitro pyrrole 
2 (30.01 g, 11.1 mmol) was added to a 500 mL round bottom flask followed by glycine ethyl 
ester hydrochloride (23.55 g, 25.5 mmol) and took up in EtOAc dried over sieves (100 mL).  A 
drop funnel was fitted to reaction flask and filled with TEA (35.5 mL) dissolved in EtOAc dried 
over sieves (50 mL).  Argon was bubbled through this solution, and this mixture was added drop 
wise over a period of 15 hours under argon.  Once all of the TEA mixture was added, the 
reaction was allowed to stir for and additional 48 hours under argon.  The white precipitate 
formed was removed by filtration and the filtrate was extracted with 1M HCl (2 x 100 mL) and 
DI water (1 x 100 mL).  The organic layer was dried over MgSO4, filtered and the solution 
concentrated by rotary evaporation to give a yellow solid 3a (28.38 g, 100%): mp 98-103 oC.  
TLC (1:1 EtOAc /Hexane) Rf = 0.52.  1H NMR data (CDCl3): δ 7.51 (d, J = 1.6 Hz, 1H), 7.12 (d, 
J = 2 Hz, 1H), 6.48 (s, 1H), 4.20 (q, J = 6.8, 7.2 Hz, 2H), 4.08 (d, J = 5.2, 2H), 3.90 (s, 3H), 1.26 
(t, J = 7.2 Hz, 3H).  13C NMR data: δ 170.12, 160.71, 134.32, 128.67, 126.11, 108.33, 60.99, 
41.16, 37.89, 14.55. 
Ethyl 3-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)propanoate (3b).  Compound 
3b was synthesized by a procedure similar to the one described above for 3a using (30.02 g, 11.1 
mmol) of 2, (17.05 g, 25.5 mmol) of β-alanine ethyl ester hydrochloride and (8.5 mL) of TEA to 
obtain 3b (27.85 g, 95%): mp 120-124 oC.  TLC (1:1 EtOAc/Hexane) Rf = 0.42.  1H NMR data 
(CDCl3): δ 7.47 (d, J = 1.2 Hz, 1H), 6.99 (d, J = 1.6, 1H), 6.62 (s, 1H), 4.12 (q, J = 7.2, 2H), 3.91 
(s, 3H), 3.58 (q, J = 6 Hz, 2H), 2.54 (t, J = 7.2 Hz, 2H), 1.22 (t, J = 7.2 Hz, 3H).  13C NMR data 
(CDCl3): δ 172.64, 160.21, 134.98, 126.64, 126.24, 106.98, 61.00, 37.86, 34.82, 33.81, 14.19. 
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Ethyl 4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)butanoate (3c).  Compound 3c 
was synthesized by a procedure similar to the one described above for 3a using (30.02 g, 11.1 
mmol) of 2, (28.05 g, 25.5 mmol) of aminobutyrate hydrochloride and (35.5 mL) of TEA to 
obtain 3c (30.56 g, 98%): mp 54-59 oC.  TLC (1:1 EtOAc/Hexane) Rf = 0.36.  1H NMR data 
(CDCl3): δ 7.54 (d, J = 1.6 Hz, 1H), 7.13 (d, J = 1.6 Hz, 1H), 6.81 (s, 1H), 4.11 (q, J = 3.6 Hz, 
7.2 Hz, 2H), 3.96 (s, 3H), 3.41 (q, J = 6.8 Hz, 6 Hz, 2H), 2.41 (t, J = 6.8 Hz, 2H), 1.92 (pentet, J 
= 6.8 Hz, 2H), 1.23 (t, J = 7.2 Hz, 3H).   13C NMR data (CDCl3): δ 173.88, 160.53, 134.84, 
126.69, 126.42, 107.03, 60.84, 39.25, 37.91, 31.98, 24.22, 21.07, 14.17. 
1-Methyl-4-nitro-N-propyl-1H-pyrrole-2-carboxamide (4).  In a flask flushed with Ar, 
the nitro pyrrole 2 (0.642 g, 2.37 mmol) was dissolved in EtOAc dried over sieves (5 mL), 
propylamine (870 µL) was added while stirring at room temperature for two days to yield 4 
(0.455 g, 91%): mp 124-130 oC.  TLC (1:1 Hexane/EtOAc) Rf = 0.53.  1H NMR data (CDCl3): δ 
7.54 (d, J = 1.6 Hz, 1H), 7.06 (d, J = 1.6 Hz, 1H), 6.09 (s, 1H), 3.98 (s, 3H), 3.35 (q, J = 6.8 Hz, 
7.2 Hz, 2H), 1.61 (m, 2H), 0.97 (t, J = 7.6 Hz, 3H).  13C NMR data (CDCl3): δ 160.37, 134.91, 
126.54, 106.59, 41.28, 37.81, 22.85, 11.36. 
Ethyl 2-(1-methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido acetate (5a).  The nitro pyrrole ester 3a (13.61 g, 53 mmol) was dissolved in 
ethanol (50 mL) in a 500 mL Parr jar,  10% water wet Pd/C (2.50 g) was added to this and the 
mixture was shaken on a hydrogenator under pressurized hydrogen (70 psi) until reaction was 
complete by TLC (100% EtOAc).  The Pd/C was filtered through celite and the filtrate 
concentrated by rotary evaporation and kept under vacuum overnight to yield a pale yellow solid.  
The amine was dissolved in EtOAc (50 mL) dried over sieves and stirred with a mechanical 
stirrer.  Once dissolved, compound 1 (14.47 g, 53 mmol) was added and allowed to stir for four 
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days.  The mixture was concentrated until minimal amount of EtOAc was present.  At which 
time the flask was placed in refrigerator over night to give yellow solid 5a (12.84 g, 79 %): mp 
222-226 oC.  TLC (100% EtOAc) Rf = 0.63.  1H NMR data (D6-DMSO): δ 10.26, 8.45 (t, J =  5.6 
Hz, 1H), 8.18 (s, 1H), 7.58 (d, J =  2 Hz, 1H), 7.27 (s, 1H), 6.92 (s, 1H), 4.11 (q, J = 6.8 Hz, 7.2 
Hz, 2H), 3.96 (s, 3H), 3.88 (d, J = 5.6 Hz, 2H), 3.81 (s, 3H), 1.21 (t, J = 7.2 Hz, 3H).  13C NMR 
data (D6-DMSO): δ 170.65, 161.84, 157.36, 134.24, 128.69, 126.73, 122.80, 121.97, 119.06, 
108.07, 104.96, 60.81, 41.15, 37.93 36.60, 14.59. 
Ethyl 3-(1-methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido) propanoate (5b).  The nitro pyrrole ester 3b (13.0 g, 48.3 mmol) was dissolved 
in ethanol (60 mL) in a 500 mL Parr jar,  10 % water wet Pd/C (1.0 g) was added to this and the 
mixture was shaken on a hydrogenator under pressurized hydrogen (70 psi) until reaction was 
complete by TLC (EtOAc).  The mixture was then acidified with concentrated HCl (4.10 mL).  
The Pd/C was filtered through celite and the filtrate concentrated by rotary evaporation and kept 
under vacuum overnight to yield a yellow solid.   In a 500 mL round bottom flask, this solid and 
nitro pyrrole 1 was dissolved in EtOAc (250 mL) dried over sieves.  TEA (17.00 mL) dissolved 
in EtOAc was added drop wise using a drop funnel.  The mixture was then allowed to stir 48 
hours at which time a yellow precipitate formed.  After the reaction was complete by TLC 
(EtOAc), the yellow precipitate was filtered then stirred in DI water for 1 hour and filtered again 
to give pure 5b (28.18 g 94%): mp 187-190 oC.  TLC (EtOAc) Rf = 0.55.   1H NMR data (D6-
DMSO): δ 10.22, 8.17 (s, 1H), 8.08 (t, J = 6 Hz, 1H), 7.57 (d, J = 2 Hz, 1H), 7.21 (s, 1H), 6.83 
(d, J =  1.6 Hz, 1H), 4.06 (q, J = 6.8 Hz, 7.2 Hz, 2H), 3.95 (s, 3H), 3.81 (s, 3H), 3.40 (m, 2H), 
1.18 (t, J = 6.8 Hz, 3H).  13C NMR data (D6-DMSO): δ 171.84, 161.64, 157.31, 134.23, 128.68, 
126.74, 123.42, 121.81, 118.57, 108.01, 104.58, 60.36, 37.93, 36.50, 35.28, 34.46, 14.56. 
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Ethyl 4-(1-methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido) butanoate (5c).  Compound 5c was synthesized by a procedure similar to the one 
described above for 5b using (31.26 g, 0.11 mol) of pyrrole 3c, (29.25 g, 0.11 mol) of 1, and 
(37.6 mL) of TEA to obtain 5c (31.15 g, 80%): mp 134-137 oC.  TLC (EtOAc) Rf = 0.54.  1H 
NMR data (CDCl3): δ 7.82 (s, 1H), 7.60 (d, J = 1.6 Hz, 1H), 7.22 (d, J = 2 Hz, 1H), 7.18 (d, J = 
1.6 Hz, 1H), 6.54 (d, J = 1.6 Hz, 1H), 6.26 (t, J = 8 Hz, 1H),  4.13 (q, J = 7.2 Hz, 2H), 4.03 (s, 
3H), 3.92 (s, 3H), 3.42 (q, J = 6.4 Hz, 2H), 1.92 (pentet, 6.8 Hz, 2H), 1.25 (t, J = 6.8 Hz, 3H).  
13C NMR data (CDCl3): δ 173.19, 161.65, 157.31, 134.24, 128.68, 126.76, 123.63, 121.78, 
118.45, 108.00, 104.49, 60.23, 38.19, 37.94, 36.49, 31.51, 25.15, 14.58. 
1-Methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-N-propyl-1H-pyrrole-2-
carboxamide (6).  Compound 4 (9.75 g 46.2 mmol) was dissolved in ethanol (60 mL) in a 500 
mL Parr jar,  10 % water wet Pd/C (5.00 g) was added to this and the mixture was shaken on a 
hydrogenator under pressurized hydrogen (70 psi) until reaction was complete by TLC (6:1 
CHCl3/MeOH).  The Pd/C was filtered through celite and the filtrate concentrated by rotary 
evaporation and kept under vacuum overnight.  This amine and nitro pyrrole 1 (12.67 g, 46.2 
mmol) was dissolved in EtOAc (20 mL) dried over sieves. The reaction was stirred for 48 hours 
at room temperature at which point a yellow precipitate formed.  After reaction was complete by 
TLC (6:1 CHCl3/MeOH) the yellow precipitate was filtered to give pure 6 (8.78 g, 56 %): mp 
220-222 oC.  TLC (6:1 CHCl3/MeOH) Rf = 0.51.  1H NMR data (CDCl3): δ 10.21 (s, 1H), 8.16 
(s, 1H), 8.03 (s, 1H), 7.56 (s, 1H), 7.19 (s, 1H), 6.83 (s, 1H), 3.94 (s, 3H), 3.79 (s, 3H), 3.11 (m, 
2H), 1.48 (m, 2H), 0.86 (t, J = 3.2 Hz, 3H).  13C NMR data (CDCl3): δ 161.57, 157.11, 134.26, 
128.64, 126.79, 123.86, 121.75, 118.33, 107.99, 104.41, 40.61, 37.92, 36.44, 23.03, 11.89 (2C). 
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Methyl 1-methyl-4-(1-methyl-4-nitro-1H-pyrrol-2carboxamido)-1H-pyrrole-2-
carboxylate (7).  Argon was bubbled through 100 mL of EtOAc containing 8.6 mL of DIEA in a 
250 mL round bottom flask.  Methyl 4-amino-1-methyl-1H-pyrrole-2-carboxylate, HCl (4.98 g, 
0.03 mol) was then added to the solution followed by nitro compound 1 (7.10 g, 0.026 mol).  The 
solution was allowed to stir under Ar for 48 hours.  The yellow precipitate that was formed was 
filtered and washed with cold DI H2O and dried under vacuum to yield yellow solid 7 (4.67 g, 58 
%): mp 235-239 oC.  TLC (1:1 Hexane/EtOAc) Rf = 0.31.  1H NMR data (D6-DMSO): δ 10.26 
(s, 1H), 8.18 (d, J = 2Hz, 1H), 7.54 (d, J = 2 Hz, 1H), 7.45 (s, 1H), 6.88 (d, J = 2 Hz, 1H), 3.94 
(s, 3H), 3.84 (s, 3H), 3.74 (s, 3H).  13C NMR data (D6-DMSO): δ 161.20, 157.41, 134.26, 
128.76, 126.56, 122.58, 121.31, 119.31, 108.77, 108.09, 51.50, 37.90, 36.72. 
1-Methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1-H-pyrrole-2-carboxylic 
acid (8).  The nitro ester 7 (1.00 g, 3.27 mmol) was suspended in EtOH (6 mL), and a solution of 
NaOH (0.654g, 5eq.) in H2O was added.  This suspension was allowed to reflux at 70 oC until 
the disappearance of 7 was indicated by TLC (EtOAc). This solution was concentrated by rotary 
evaporation to dryness to produce a yellow solid.  The yellow solid was then dissolved in 2 mL 
of H2O.  This solution was then cooled to 0 oC and acidified with concentrated HCl until the pH 
was 1.  At this point a yellow precipitate fell out of solution and was filtered to yield 8 (0.789 g, 
83%): mp 215-218 oC. TLC (6:1 CHCl3:MeOH) Rf = 0.42.  1H NMR data (D6-DMSO): δ 10.23 
(s, 1H), 8.18 (d, J = 1.6 Hz, 1H), 7.54 (d, J = 2 Hz, 1H), 7.41 (d, J = 2 Hz, 1H), 6.82 (d, J = 2 Hz, 
1H), 3.94 (s, 3H), 3.82 (s, 3H).  13C NMR data (D6-DMSO): δ 162.34, 1.57.35, 134.25, 128.73, 
126.61, 122.36, 120.87, 120.26, 108.82, 108.19, 37.94, 36.69. 
2-(1-Methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido)acetic acid (9a).  Compound 5a (3.03 g, 7.95 mmol) was dissolved in EtOH (20 
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mL) in a 100 mL round bottom flask to this NaOH (1.27 g, 4 eq.) and H2O (5 mL) solution was 
added and allowed to reflux until the disappearance of 5a by TLC (6:1 CHCl3/MeOH).  This 
solution was then concentrated by the removal of the EtOH.  The aqueous solution was then 
cooled in an ice/water bath and the medium was acidified by concentrated HCl until the pH was 
1.  A yellow solid was produce and filtered to give yellow solid 9a (2.61g, 94%): mp 262-264 
oC. TLC (1:1 CHCl3/MeOH) RF = 0.27.  1H NMR data (D6-DMSO): δ 12.5 (s, 1H), 10.30 (s, 
1H), 8.20 (d, J = 2Hz, 1H), 7.60 (d, J = 2 Hz, 1H), 7.29 (d, J = 2Hz, 1H), 6.92 (d, J = 1.6 Hz, 
1H), 3.97 (s, 3H), 3.82 (d, J = 3.6 Hz, 5H).  13C NMR data (D6-DMSO): δ 172.10, 161.77, 
157.35, 134.23, 128.69, 126.74, 122.95, 121.95, 118.94, 108.10, 104.87, 37.94, 36.60. 
3-(1-Methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido)propanoic acid (9b).  Compound 9b was synthesized using a procedure similar to 
the ones described above for 9a using (2.01 g, 5.7 mmol) of 5b and NaOH (0.92 g, 4 eq.) to give 
yellow solid 9b (1.81 g, 98 %): mp 226-230 oC.  TLC (5:2 CHCl3/MeOH) Rf = 0.38.  1H NMR 
data (D6-DMSO): δ 12.2 (s, 1H), 8.47, (s, 1H), 8.07 (s, 1H), 7.57 (s, 1H), 7.20 (s, 1H), 6.84 (s, 
1H), 3.95 (s, 3H), 3.80 (s, 3H).  13C NMR data (D6-DMSO): δ 173.69, 161.61, 157.32, 134.21, 
128.66, 126.73, 123.44, 121.87, 118.56, 108.19, 104.62, 37.97, 36.52, 35.41, 34.72. 
4-(1-Methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido)butanoic acid (9c).  Compound 9c was synthesized using a procedure similar to 
the ones described above for 9a using (2.00 g, 4.9 mmol) of 5c and NaOH (0.789 g, 4 eq.) to 
give yellow solid 9c (1.78 g, 96 %): mp 240-245 oC.  TLC (5:2 CHCl3/MeOH) Rf = 0.39. 1H 
NMR data (D6-DMSO): δ 10.29 (s, 1H), 8.37 (s, 1H), 8.15 (d, J = 2 Hz, 1H), 7.57 (d, J = 2 Hz, 
1H), 7.19 (d, J = 1.6 Hz, 1H), 6.83 (d, J = 1.6 Hz, 1H), 3.93 (s, 3H), 3.80 (s, 3H), 3.13 (q, J = 5.6 
Hz, 6.4 Hz, 2H), 2.46 (t, J = 7.2 Hz, 2H), 1.66 (t, J = 7.2 Hz, 3H).  13C NMR data (D6-DMSO): δ 
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174.75, 161.63, 157.29, 134.23, 128.67, 126.75, 123.67, 121.77, 118.41, 108.01, 104.46, 38.29, 
37.94, 36.48, 31.60, 25.19. 
2-Deoxy-2-(4-methoxybenzylidene)amino-β-D-glucopyranose. (IUPAC: (E)-6-
(hydroxymethyl)-3-(3-methoxybenzylideneamino)tetrahydro-2H-pyran-2,4,5-triol) (10).  
Synthesized from D-glucosamine hydrochloride as described in literature.28  In a 500 mL round 
bottom flask cooled to 0 oC sodium hydroxide (11.18 g, 0.279 mols) was dissolved in 234 mL of 
DI water while stirring.  D-glucosamine (50.00 g, 0.232 mols) was then added and in 5 minutes 
the solution turned clear.  4-methoxybenzaldehyde (31.0 mL, 0.254 mols) was added to form a 
two layer mixture which was stirred for 30 minutes at 0 oC.  The mixture was then allowed to sit 
in the refrigerator over night to yield a white precipitate that was filtered under vacuum until 
dryness to give 9 (42.83 g, 62%): mp 153-154 oC.  1H NMR data (D6-DMSO): δ 8.10 (s, 1H), 
7.67 (d, J = 8.4 Hz, 2H), 6.97 (d, J = 8.8 Hz, 2H), 6.52 (s, 1H), 4.93 (d, J = 5.2 Hz, 1H), 4.91 (d, 
J = 5.2 Hz, 1H), 4.67 (d, J = 8.8 Hz, 1H), 4.55 (t, J = 5.6 Hz, 1H), 3.79 (s, 3H),  3.71 (dd, J = 3 
Hz, 7.7 Hz, 1H), 3.42 (m, 2H), 3.21 (m, 1H), 3.13 (m, 1H), 2.77 (t, J = 8 Hz, 1H).  13C NMR data 
(D6-DMSO): δ 161.66, 161.49, 130.07, 129.56 (2C), 114.35, 96.08, 79.64, 78.65, 77.32, 75.04, 
70.80, 61.72, 55.72. 
1,3,4,6-Tetra-O-actyl-2-deoxy-2-(4-mehtoxybenzylidene)amino-β-D-glucopyranose. 
(IUPAC: (E)-6-(acetoxymethyl)-3-(3-methoxybenzylideneamino)tetrahydro-2H-pyran-
2,4,5-triyl triacetate) (11). Compound 11 was synthesized as described in literature.28  Pyridine 
(250 mL) was dried over sieves.  The imine 10 (48.02g, 0.142 mmol) was dissolved in pyridine 
(236 mL) at 0oC in an ice water bath.  Once dissolved acetic anhydride (142 mL) was added and 
the flask was immediately removed from ice water bath.  The temperature was allowed to reach 
room temperature overnight while stirring.  The volume of the solution was reduced to half by 
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distillation under vacuum.  The solution was then poured into ice water (~2000 mL) forming a 
white precipitate.  The solution was allowed to stir for 1 hour and then placed in refrigerator 
overnight.  The white precipitate was then filtered under vacuum to give 11 (54.47 g, 83%): mp 
169-171oC.  1H NMR data (D6-DMSO): δ 8.29 (s, 1H), 7.64 (d, J = 8.8 Hz, 2H), 6.97 (d, J = 8.4 
Hz, 2H), 6.05 (d, J = 8.4, 1H), 5.43 (t, J = 9.6 Hz, 1H), 4.96 (t, J = 9.6 Hz, 1H), 4.26 (m, 2H), 
4.00 (d, J = 10.81, 1H), 3.78 (s, 3H), 3.44 (t, J = 8.4 Hz, 2H), 2.06 (s,3H), 1.97 (s, 3H), 1.96 (s, 
3H), 1.81 (s, 3H).  13C NMR data (D6-DMSO): δ 170.50, 169.89, 169.43, 169.05, 164.90, 
162.27, 130.37 (2C), 128.71, 114.65 (2C), 92.97, 72.78, 72.68, 71.96, 68.24, 62.10, 55.82, 20.99, 
20.91, 20.90, 20.65.  
1,3,4,6-Tetra-O-acetyl-2-amino-2-deoxy-β-D-glucopyranose hydrochloride. (IUPAC: 
6-(acetoxymethyl)-3-aminotetrahydro-2H-pyran-2,4,5-triyl triacetate hydrochloride) (12).  
Compound 12 was synthesized as described in literature.28  Acetyl chloride (3.95 mL) was added 
to anhydrous methanol (27.38 mL) in a 100 mL round bottom flask at 0 oC with constant stirring 
for 1 hour.  This solution was then added to a stirred solution of imine 10 (25.04 g, 50.7 mmol) 
in acetone (770.6 mL) at room temperature.  This mixture was stirred for 1 hour and then cooled 
to 0 oC.  To the cooled solution ether (273.8 mL) was added and stirred for an additional 45 min. 
at 0 oC.  A white precipitate was filtered under vacuum to give 11 (18.92 g, 97%): mp 120 oC- 
decomposition.  1H NMR data (D6-DMSO): δ 8.42 (s, 3H), 5.85 (d, J = 8.8, 1H), 5.31 (t, J = 9.6 
Hz, 1H), 4.96 (t, J = 9.6 Hz, 1H), 4.26 (m, 2H), 4.00 (d, J = 10.8 Hz, 1H), 3.78 (s, 3H), 3.44 (t, J 
= 8.4 Hz, 2H), 2.15 (s, 3H), 2.02 (s,3H), 1.99 (s, 3H), 1.97 (s, 3H).  13C NMR data (D6-DMSO): 
δ 170.41, 170.26, 169.76, 169.09, 90.56, 72.06, 70.78, 68.23, 61.70, 52.55, 21.37, 21.29, 20.94, 
20.80. 
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 (2S,3R,4R,5S,6R)-6-(Acetoxymethyl-3-(2-(1-methyl-4-(1-methyl-4-nitro-1H-
pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)acetamido)tetrahydro-2H-pyran-2,4,5-
triyl triacetate (13a).  In a flask flushed with Ar, 12 (2.03g, 53 mmol) was dissolved in 8 mL 
anhydrous DMF along with EDCI (1.57 g, 1.5 eq.), DMAP (1.62 g, 2.5 eq.), HOBT (1.27 g, 1.57 
eq.), and CuCl2 (71 mg, 0.01 eq.).  Once in solution, the carboxylic acid 9a (2.00 g, 53 mmol) 
was then added and allowed to stir at room temperature over 48 hours until the disappearance of 
starting material by TLC (3:1 EtOAc/MeOH).  This solution was diluted with DCM (100 mL) 
and extracted with H2O (150 mL, 2x), sat. NaHCO3 (100 mL, 2x), and 1M HCl (100mL, 2x).  
The organic layer was dried over MgSO4.  The solution was filtered and concentrated by rotary 
evaporation until a solid began to fall out of solution.  The solution was warmed up again until 
the solid redissolved and then allowed to slowly reach room temperature overnight at which 
point an orange-brown solid fell out of solution.  The flask was then placed in the refrigerator to 
cool further for 24 hours.  The crystals were then filtered and dried to give 13a (3.18 g, 87%): 
mp 118-121 oC. TLC (6:1 CHCl3/MeOH) Rf  = 0.52.  1H NMR data (D6-DMSO): δ 10.27 (s, 1H), 
8.4 (t, J = 8.4 Hz, J = 10 Hz, 1H), 8.18 (d, J = 2 Hz, 1H), 7.83 (d, J = 9.6, 1H), 7.59 (d, J = 1.6, 
1H), 7.26 (d, J = 2 Hz, 1H), 6.88 (d, J = 2 Hz, 1H), 5.73 (d, J = 8.8 Hz, 1H), 5.24 (t, J = 9.6, 1H), 
4.86 (t, J = 9.6 Hz, 1H), 4.18 (dd, J = 4.4 Hz, 4Hz, 8.4 Hz, 1H), 4.03 (m, 2H), 3.98 (s, 3H), 3.77 
(3H), 3.62 (d, J = 6 Hz, 2H), 2.05 (s, 3H) ,1.99 (s, 3H), 1.94 (s, 3H), 1.94 (s, 3H).  13C NMR data 
(D6-DMSO): δ 171.25, 170.47, 170.05, 169.71, 169.31, 161.31, 161.59, 157.32, 134.24, 128.66, 
126.75, 123.48, 121.81, 118.58, 108.02, 104.43, 92.15, 72.62, 71.99, 68.52, 61.96, 52.35, 37.92, 
36.48, 36.01, 35.84, 20.95 (2C), 20.85, 20.68. 
(2S,3R,4R,5S,6R)-6-(Acetoxymethyl-3-(3-(1-methyl-4-(1-methyl-4-nitro-1H-pyrrole-
2-carboxamido)-1H-pyrrole-2-carboxamido)propanamido)tetrahydro-2H-pyran-2,4,5-triyl 
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triacetate (13b).  Compound 13b was synthesized using a procedure similar to the one described 
for 13a using (4.44 g, 12.2 mmol) of 9b and (4.69 g, 12.2 mmol) of 12 to give a yellow solid 13b 
(6.62 g, 77 %): mp 175-179 oC.  TLC (6:1 CHCl3/MeOH) Rf = 0.46.  1H NMR data (D6-DMSO): 
δ 10.23 (s, 1H), 8.18 (d, J = 2 Hz, 1H), 8.10 (d, J = 8.8 Hz, 1H), 8.03 (t, J = 5.2 Hz, 1H), 7.57 (d, 
J = 4 Hz, 1H), 7.22 (d, J = 1.6 Hz, 1H), 6.81 (d, J = 1.6 Hz, 1H), 5.72 (d, J = 8.8 Hz, 1H), 5.18 (t, 
J = 9.6 Hz, 1H), 4.88 (t, J = 9.6 Hz, 1H), 4.19 (dd, J = 4.4 Hz, J = 4.8 Hz, J = 7.6 Hz, 1H), 3.98 
(m, 3H), 3.96 (s, 3H), 3.80 (s, 3H), 2.31 (t, J = 7.2 Hz, 2H), 2.0 (s, 3H), 1.99 (s, 3H), 1.97 (s, 
3H), 1.88 (s, 3H).  13C NMR data (D6-DMSO): δ 171.25, 170.47, 170.05, 169.71, 169.31, 
161.59, 157.32, 134.24, 128.66, 126.75, 123.48, 121.81, 118.58, 104.43, 92.15, 72.62, , 71.99, 
68.52, 61.96, 52.35, 37.92, 36.48, 36.01, 35.84, 20.95 (2C), 20.85, 20.68. 
(2S,3R,4R,5S,6R)-6-(Acetoxymethyl-3-(4-(1-methyl-4-(1-methyl-4-nitro-1H-pyrrole-
2-carboxamido)-1H-pyrrole-2-carboxamido)butanamido)tetrahydro-2H-pyran-2,4,5-triyl 
triacetate (13c).  Compound 13c was synthesized using a procedure similar to the one described 
for 13a using (3.25 g, 8.6 mmol) of 9c and of 12 (3.00 g, 7.82 mmol) to give to give a yellow 
solid 13c (4.88g, 86 %): mp 171-176 oC. TLC (6:1 CHCl3/MeOH) Rf  = 0.44.  1H NMR data 
(D6-DMSO): δ 10.23 (s, 1H), 8.17 (s, 1H), 8.05 (m, 2H), 7.19 (s, 1H), 6.84 (s, 1H), 5.70 (d, J = 
8Hz, 1H), 5.17 (t, J = 9.6 Hz, 1H), 4.88 (t, J = 9.6 Hz, 1H), 4.17 (dd, J = 4.4 Hz, J =  8.4 Hz, 1H), 
4.0 (m, 3H), 3.96 (s, 3H), 3.79 (s, 3H), 3.10 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H), 2.01 (s, 3H), 1.89 
(s, 3H), 1.64 (m, 2H).  13C NMR data (D6-DMSO): δ 172.67, 170.48, 170.04, 169.34, 161.56, 
157.30, 134.23, 128.67, 126.75, 123.64, 121.77, 118.43, 108.00, 104.43, 92.18, 72.62, 71.97, 
68.52, 61.93, 52.23, 38.42, 37.93, 36.48, 33.71, 26.13, 20.96 (2C), 20.86, 20.77. 
Ethyl 2-(4-(4-acrylamido-1-methyl-1H-pyrrole-2-carboxamido)1-methyl-1H-
pyrrole-2-carboxamido)acetate (14a).  Compound 5a (2.04 g, 5.4 mmol) was dissolved in 50 
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mL of ethanol and 1.72 g 10 % water wet Pd/C was added in a Parr jar.  The mixture was shaken 
under pressurized hydrogen (70 psi) until 5a had disappeared by TLC (EtOAc).  The Pd/C was 
filtered through celite and the filtrate was concentrated by rotary evaporation.  The residue was 
placed under high vacuum overnight.  The flask was flushed with N2 and the residue was 
dissolved in anhydrous THF (20 mL) and DIEA (3.13 mL, 24 mmol).  The solution was bubbled 
with N2 and cooled to -40 oC for 1 hour.  Acryloyl chloride (489 µL, 0.5 mmol) was the added to 
the cooled solution drop wise.  The reaction temperature was maintained between -40 oC to -20 
oC and protected from light.  The reaction continued until it was complete by TLC (6:1 
CHCl3/MeOH).  The solution was concentrated by rotary evaporation, re-dissolved in DCM (50 
mL) and extracted with DI water (2 x 60 mL).  The organic layer was dried over MgSO4.  The 
solution was concentrated by rotary evaporation until dry to give pure 14a (2.11 g, 97 %): mp 
101-106 oC.  TLC (6:1 CHCl3/MeOH) Rf = 0.66.  1H NMR data (D6-DMSO): δ 10.12 (s, 1H), 
9.94 (s, 1H), 8.40 (t, J = 5.6 Hz, 1H), 7.24 (d,  J = 9.6 Hz, 2H), 6.9 (s, 2H), 6.35 (m, 1H), 6.17 
(dd, J = 1.6 Hz, 1H), 5.66 (dd, J = 1.6 Hz, 1H), 4.10 (q, J = 6.8 Hz, 2H), 3.87 (d, J = 5.7 Hz, 2H), 
3.83 (s, 3H), 3.78 (s, 3H), 1.18 (t, J = 8 Hz, 3H).  13C NMR data (D6-DMSO): δ 170.68, 162.14, 
161.95, 158.81, 131.92, 126.11, 123.45, 122.62, 122.53, 122.14, 118.95, 105.14, 104.51, 60.82, 
36.63, 36.52, 14.59. 
 Ethyl 3-(4-(4-acrylamido-1-methyl-1H-pyrrole-2-carboxamido)1-methyl-1H-
pyrrole-2-carboxamido)propanoate (14b).  Compound 14b was synthesized using a procedure 
similar to the one described for 14a using 351 mg, (0.90 mmol) of 5b, 81 µL (0.98 mmol) of 
acryoloyl chloride and 515 µL (3.1 mmol) of DIEA to yield 14b as a brown solid (0.329 g, 
88%): mp 66-71 oC.  TLC (6:1 CHCl3/MeOH) Rf = 0.39.  1H NMR data (D6-DMSO): δ 10.10 (s, 
1H), 9.88 (s, 1H), 8.03 (t, J = 4.9 Hz, 1H), 7.23 (d, J = 1.6 Hz, 2H), 7.16 (d, J = 1.6 Hz, 1H), 6.88 
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(d, J = 1.6 Hz, 1H), 6.81 (d, J = 1.6 Hz, 1H), 6.35 (m, 1H), 6.15 (dd, J =  2 Hz, 1H), 5.63 (dd, J = 
5 Hz, 1H), 4.03 (q, J = 6.5 Hz, 7.2 Hz 2H), 3.81 (s, 3H), 3.76 (s, 3H), 1.15 (t, J = 7.2 Hz, 3H).  
13C NMR (D6-DMSO): δ 171.86, 162.10, 161.75, 158.76, 131.97, 123.45, 123.12, 122.50, 
122.15, 118.91, 118.45, 104.74, 104.45, 60.36, 36.64, 36.43, 35.26, 34.48, 31.17, 14.56. 
Ethyl 4-(4-(4-acrylamido-1-methyl-1H-pyrrole-2-carboxamido)1-methyl-1H-
pyrrole-2-carboxamido)butanoate (14c).  Compound 14c was synthesized using a procedure 
similar to the one described for 14a using 421 mg, (1.04 mmol) of 5c, 94 µL (1.14 mmol) of 
acryoloyl chloride and 603 µL (3.6 mmol) of DIEA to yield 14c as a brown solid (0.350 g, 79%): 
mp 75-80 oC.  TLC (6:1 CHCl3/MeOH) Rf = 0.63. 1H NMR data (D6-DMSO): δ 10.11 (s, 1H), 
9.89 (s, 1H), 8.03 (t, J = 5.5 Hz, 1H), 7.26 (d, J = 1.6 Hz, 1H), 7.17 (d, J = 1.6 Hz, 1H), 6.90 (d, J 
= 1.6 Hz, 1H), 6.84 (d, J =1.6 Hz, 1H), 6.35 (m, 1H), 6.17 (dd, J = 2 Hz, 14.8 Hz, 1H), 5.65 (dd, 
J = 2 Hz, 8 Hz, 1H), 4.03 (q, J = 6.8 Hz, 7.2 Hz), 3.83 (s, 3H), 3.78 (s, 3H), 3.17 (q, J = 6.4 Hz, 6 
Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 1.73 (m 2H), 1.17 (t, J = 6.8 Hz, 3H).  13C NMR (D6-DMSO): 
δ 173.18, 162.09, 161.75, 158.74, 131.95, 126.06, 123.48, 123.33, 122.45, 122.14, 118.89, 
118.32, 104.63, 104.41, 60.22, 38.16, 36.65, 36.42, 31.50, 25.17, 14.58. 
2-(4-(4-Acrylamido-1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-
carboxamido)acetic acid (15a). Compound 14a (1.28 g, 3.18 mmol) was dissolved in reagent 
acetone (16 mL). NaOH (0.501 g, 1.2 mmol) dissolved in 4 mL of DI H2O was added to the 
reaction flask.  After 1 hour no starting material was left as indicated by TLC (6:1 
CHCl3:MeOH).  The acetone was removed by rotary evaporation completely leaving the DI 
H2O.  The flask was then cooled in an ice/water bath at which point the pH of the medium was 
adjusted to 1 with concentrated HCl producing a brown precipitate.  The brown precipitate was 
filtered by vacuum filtration to give pure 15a (0.894, 72 %): mp 130-133 oC. TLC 2:1 
 74
(CHCl3:MeOH) Rf = 0.52.  1H NMR data (D6-DMSO): δ 10.15 (s, 1H), 9.94 (s, 1H), 8.312 (t, J = 
5 Hz, 1H), 7.26 (s, 1H), 7.23 (s, 3H), 6.91 (d, J = 5.8 Hz, 2H), 6.37 (m, 1H), 6.17 (dd, J = 2 Hz, 
1H), 5.65 (dd, 2.4 Hz, 8 Hz, 1H), 3.91 (d, J = 6 Hz, 2H), 3.84 (s, 3H), 3.83 (s, 3H).  13C NMR 
(D6-DMSO): δ 172.21, 162.12, 161.88, 131.98, 126.02, 123.49, 122.73, 122.17, 118.82, 105.07, 
104.52, 65.38, 36.62, 36.50, 15.63. 
3-(4-(4-Acrylamido-1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-
carboxamido)propanoic acid (15b).  Compound 15b was synthesized using a procedure similar 
to the one described for 15a using (250 mg, 0.602 mmol) of 14b and 0.096 g of NaOH (2 mmol) 
to yield 15b as a brown solid (0.163 g, 70 %): mp 107-110 oC. TLC 5:2 (CHCl3:MeOH) Rf = 
0.30.  1H NMR data (D6-DMSO): δ 10.08 (s, 1H), 9.85 (s, 1H), 7.98 (t, J = 5 Hz, 1H), 7.21 (s, 
1H), 7.13 (s, 1H), 6.85 (s, 1H), 6.78 (s, 1H), 6.31 (m, 1H), 6.12 (d, J = 1.6 Hz, 1H), 3.82 (s, 3H), 
3.78 (s, 3H), 3.31 (t, J = 6.4 Hz, 2H).  13C NMR (D6-DMSO): δ 173.48, 162.11, 161.72, 158.75, 
131.98, 123.46, 123.16, 122.49, 122.15, 118.91, 118.42, 104.72, 104.45, 36.65, 36.44, 35.30, 
34.49, 21.54. 
 4-(4-(4-Acrylamido-1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-
carboxamido)butanoic acid (15c).  Compound 15c was synthesized using a procedure similar 
to the one described for 15a using (285 mg, 0.66 mmol) of 14c and 0.106 g of NaOH (2.6 mmol) 
to yield 15c as a brown solid (0.208 g, 78%): mp 71-76oC. TLC 5:2 (CHCl3:MeOH) Rf  = 0.63.  
1H NMR data (D6-DMSO): δ 10.16 (s, 1H), 9.90 (s, 1H), 8.04 (t, J= 4.8 Hz, 1H), 7.25 (s, 1H), 
7.17 (s, 1H), 6.90 (s, 1H), 6.84 (s, 1H), 6.37 (m, 1H), 6.18 (dd, J =1.3 Hz, 1H), 5.66 (dd, J = 1.2 
Hz, 8.8 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 3H), 3.17 (t, J = 6.2 Hz, 2H), 2.23 (t, J = 7.2 Hz, 2H), 1.70 
(pentet, J = 6.5 Hz, 6.8 Hz, 7.32 Hz, 2H).  13C NMR (D6-DMSO): δ 175.23, 174.80, 162.16, 
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161.78, 158.77, 131.90, 126.02, 123.47, 123.36, 122.42, 122.12, 118.85, 118.34, 104.66, 104.46, 
38.27, 36.64, 36.41, 31.60, 25.20. 
6-(Acetoxymethyl)-3-(2-(4-(4-acrylamido-1-methyl-1H-pyrrole-2-carboxamido)-1-
methyl-1H-pyrrole-2-carboxamido)acetamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate 
(16a).  In a flask flushed with N2, 15a (0.849 g, 2.27 mmol) was dissolved in 2 mL of anhydrous 
DMF along with EDCI (0.657 g, 1.5 eq.), DMAP (0.701 g, 2.5 eq.), HOBT (0.926 g, 3.0 eq,), 
CuCl2 (0.031 g, 0.1 eq.), and the amine hydrochloride 12 (0.960 g, 2.5 mmol) was added and the 
solution was allowed to stir at room temperature over a period of two days.  The solution was 
diluted with 100 mL DCM and the organic layer extracted with H2O (2 x, 150 mL), sat. NaHCO3 
(2 x, 150 mL), and 1M HCl (2 x, 150 mL).  The organic layer was then dried over MgSO4.  The 
resulting solution was rotary evaporated until dry to yield the product, 16a as brown-orange 
solid. (1.36 g, 85 %): mp 135-138 oC. TLC (6:1 CHCl3/MeOH) Rf  = 0.74. 1H NMR (D6-
DMSO): δ 10.09 (s, 1H), 9.93 (s, 1H), 8.31 (t, J = 2.8 Hz, 1H), 7.81 (d, J = 9.2 Hz, 1H), 7.24 (d, 
J = 10 Hz, 2H), 6.91 (d, J = 14 Hz, 2H), 6.37 (m, 1H), 6.17 (dd, J = 2.8 Hz, 15.6 Hz, 5.74 (d, 8.8 
Hz, 1H), 5.65 (dd, J = 3.2 Hz, 8 Hz, 1H), 4.18 (dd, 8.8 Hz, 7.6 Hz, 1H), 3.93 (s, 3H), 3.82 (s, 
3H), 3.62 (d, J = 5.6 Hz, 2H), 2.06 (s, 3H), 2.05 (s, 3H), 1.99 (s, 3H), 1.95 (s, 3H).  13C NMR 
(D6-DMSO): δ 170.49, 170.26, 170.09, 169.72, 169.42, 162.12, 162.02, 158.81, 131.97, 123.48, 
122.87, 122.15, 118.91, 118.75, 105.03, 104.55, 92.20, 72.31, 72.01, 68.77, 61.96, 52.07, 43.08, 
36.62, 36.42, 21.02, 20.95, 20.86, 20.84. 
6-(Acetoxymethyl)-3-(3-(4-(4-acrylamido-1-methyl-1H-pyrrole-2-carboxamido)-1-
methyl-1H-pyrrole-2-carboxamido) propanamido)tetrahydro-2H-pyran-2,4,5-triyl 
triacetate (16b).  Compound 16b was synthesized similar to the procedure described above for 
16a using 0.147 g (0.379 mmol) of 15b, 2 mL anhydrous DMF along with, EDCI (0.108 g, 1.5 
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eq.), DMAP (0.112 g, 2.5 eq.), HOBT (0.151 g, 3.0 eq,), and CuCl2 (0.007 g, 0.1 eq.) and 0.149 
g (0.388 mmol) of 12 to yield 16b as a brown-orange solid (0.260 g, 95 %): mp 131-136 oC. 
TLC (6:1 CHCl3/MeOH) Rf  = 0.50. 1H NMR (D6-DMSO): δ 10.09 (s, 1H), 9.93 (s, 1H), 8.31 (t, 
J = 4.8 Hz, 1H), 7.81 (d, J = 9.2 Hz, 1H), 7.24 (d, J = 10 Hz, 2H), 6.91 (d, J = 14 Hz, 2H), 6.80 
(d, J = 1.6 Hz, 1H), 6.36 (m, 1H), 6.18 (dd, J = 2 Hz, 15 Hz, 1H), 5.65 (dd, J = 2 Hz, 8 Hz, 1H), 
5.17 (t, J = 10 Hz,  1H), 4.88 (t, J = 9.9 Hz, 1H), 4.18 (dd, J = 5.2 Hz, 8Hz, 1H), 3.97 (m, 2H), 
3.82 (s, 3H), 3.78 (s, 3H), 2.54 (t, J = 1.6 Hz, 2H), 2.30 (q, J = 1.6 Hz, 7.2 Hz, 2H), 2.00 (s, 3H), 
1.99 (s, 3H), 1.96 (s, 3H), 1.87 (s, 3H). 13C NMR (D6-DMSO): δ 171.26, 170.50, 170.07, 
169.73, 169.34, 162.09, 161.68, 158.74, 131.96, 126.05, 123.45, 123.15, 122.48, 122.12, 118.86, 
118.41, 104.58, 104.32, 92.12, 72.61, 71.96, 68.46, 61.93, 52.29, 36.46, 36.42, 36.26, 36.03, 
35.83, 20.97, 20.87 (2C), 20.70. 
6-(Acetoxymethyl)-3-(4-(4-(4-acrylamido-1-methyl-1H-pyrrole-2-carboxamido)-1-
methyl-1H-pyrrole-2-carboxamido)butanamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate 
(16c).  Compound 16c was synthesized similarly to the procedure described above for 16a using 
0.240 g (0.598 mmol) of 15c, 2 mL anhydrous DMF along with, EDCI (0.174 g, 1.5 eq.), DMAP 
(0.183 g, 2.5 eq.), HOBT (0.243 g, 3.0 eq,), and CuCl2 (0.010 g, 0.1 eq.) and 0.230 g (0.599 
mmol) of 12 to yield 16c as a brown-orange solid (0.432 g, 98 %): mp 136-139 oC. TLC (6:1 
CHCl3/MeOH) Rf = 0.40. 1H NMR (D6-DMSO): δ 10.09 (s, 1H), 9.89 (s, 1H), 8.02 (t, J = 9.2 
Hz, 1H), 7.26 (d, J = 1.2 Hz, 1H), 7.17 (d, J = 1.2 Hz, 1H), 6.90 (d, J = 1.6 Hz, 2H), 6.83 (d, J = 
1.6 Hz, 1H), 6.33 (m, 1H), 6.15 (dd, J = 1.6 Hz, 15.2 Hz, 1H), 5.70 (d, J = 8.8 Hz, 1H), 5.65 (dd, 
J = 1.6 Hz, 8.4 Hz, 1H), 5.16 (t, J = 10 Hz, 1H), 4.88 (t, J = 9.6 Hz, 1H), 4.17 (dd, J = 4.4 Hz, 8 
Hz, 1H), 4.00 (m, 4H), 3.82 (s, 3H), 3.78 (s, 3H), 3.11 (q, J = 5.2 Hz, 6 Hz, 2H), 2.04 (s, 3H), 
2.00 (s, 3H), 1.97 (s, 3H), 1.91 (s, 3H), 1.64 (pentet, J = 7.5 Hz, 6.9 Hz, 14 Hz, 2H).  13C NMR 
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(D6-DMSO): δ 172.70, 170.52, 170.07, 169.74, 169.38, 162.10, 161.69, 158.75, 131.93, 126.10, 
123.47, 123.34, 122.43, 122.13, 118.32, 105.03, 104.60, 92.17, 72.61, 71.96, 68.49, 61.91, 52.24, 
49.06, 36.65, 36.42, 33.72, 26.17, 20.97, 20.87 (2C), 20.78. 
1-Methyl-4-(1-methyl-4-(3-methylsulfonyl)propanamido)-1H-pyrrole-2-
carboxamido)-N-propyl-1H-pyrrole-2-carboxamide (17).  Compound 6 (0.166 g, 0.410 
mmol) was dissolved in 50 mL of ethanol and 0.120 g 10% water wet Pd/C was added in a Parr 
jar.  The mixture was shaken under pressurized hydrogen (70 psi) until 6 had disappeared by 
TLC (6:1 CHCl3/MeOH).  The Pd/C was filtered through celite and the filtrate was concentrated 
by rotary evaporation.  The residue was placed under high vacuum overnight.  The flask 
containing the reduced compound 6 was flushed with N2 and dissolved with 4 mL of anhydrous 
DMF and anhydrous DIEA (289 µL, 1.7 mmol).  The mixture was cooled to -40 0C for 45 
minutes.  The 3-(methylsulfonyl) propanoyl chloride (0.094 g, 0.55 mmol) was then added to the 
cooled mixture and the temperature was allowed to slowly reach RT until TLC 
(6:1CHCl3/MeOH) indicated the disappearance of the reduced compound 6.  The solvent was 
then removed by rotary evaporation and the solid was took up in 100 mL of DCM and extracted 
with HCl (2x, 100 mL) and DI H2O (2x, 100 mL).  The organic layer was then dried over 
MgSO4.  The resulting solution was concentrated by rotary evaporation to yield the crude 
product and purified with flash column chromatography (9:1 EtOAc/MeOH) to give pure 17 
(0.055 g, 25 %):  mp > 150 oC. TLC (9:1 EtOAc/MeOH) Rf = 0.36. 1H NMR (D6-DMSO): δ 
10.0 (s, 1H), 9.83 (s, 1H), 7.96 (t, J = 5.2 Hz, 1H), 7.15 (d, J = 1.6 Hz, 2H), 6.83 (d, J = 9.6 Hz, 
2H), 3.81 (s, 3H), 3.77 (s, 3H), 3.10 (m, 2H), 2.99 (s, 3H), 2.72 (t, J = 7.6 Hz, 2H), 1.47 (q, J = 
7.2 Hz, 2H), 0.85 (t, J = 7.2 Hz, 3H).  13C NMR (D6-DMSO): δ 166.57, 161.70, 158.78, 123.55, 
123.33, 122.39, 122.12, 118.65, 118.22, 104.59, 104.33, 50.22, 36.59, 36.36, 28.68, 23.03, 11.89. 
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6-(Acetoxymethyl)-3-(2-(1-methyl-4-(1-methyl-4-(3-(methylsulfonyl)propanamido)-
1H-pyrrole-2-carboxamido)acetamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate (18a).  
Compound 16a (0.317 g, 0.467 mmol) was dissolved in 52 mL of ethanol and 0.412 g 50 % 
water wet Pd/C was added in a Parr jar.  The mixture was shaken under pressurized hydrogen (70 
psi) until 16a had disappeared by TLC (6:1 CHCl3/MeOH).  The Pd/C was filtered through celite 
and the filtrate was concentrated by rotary evaporation.  The residue was placed under high 
vacuum overnight.  The flask with flushed with N2 and the reduced compound 16a was dissolved 
in 2.5 mL of anhydrous DMF along anhydrous DIEA (193 µL, 1.1 mmol) and cooled to  
-40 oC in a dry ice acetone bath for 45 minutes.  3-(methylsulfonyl)propanoyl chloride (0.081 g, 
0.467 mmol) was then added and temperature was allowed to reach room temperature over night.  
The reaction stirred for two days at room temperature until the disappearance of the reduced 
compound 16a was indicated by TLC (6:1 CHCl3/MeOH).  The solution was diluted with 50 mL 
DCM and the organic solution was extracted with H2O (2x, 60 mL), 1 M HCl (2x, 50 mL), and 
sat. NaHCO3 (2x, 50 mL).  The organic layer was then dried over MgSO4.  The resulting 
solution was rotary evaporated until dry to yield the product, 18a as an orange solid (0.170 g, 46 
%):  mp 94-97 oC. TLC (6:1 CHCl3/MeOH) Rf = 0.64.  1H NMR (D6-DMSO): δ 10.06 (s, 1H), 
9.92 (s, 1H), 8.33 (t, J = 12 Hz, 1H), 7.23 (d, J = 8 Hz, 2H), 6.87 (dd, J = 1.6 Hz, 2 Hz, 2H), 5.73 
(d, J = 8.8 Hz, 1H), 5.24 (t, J = 10 Hz, 1H),  4.85 (t, J = 9.2 Hz, 1H), 4.17 (dd, J = 4.4 Hz, 8.3 Hz, 
1H), 3.95 (m, 3 H), 3.63 (d, J = 5.6 Hz, 2H),  3.39 (t, J = 11.2 Hz, 2H), 3.00 (s, 3H), 2.058 (s, 
3H), 1.99 (s, 3H), 1.95 (s, 3H), 1.94 (s, 3H).  13C NMR (D6-DMSO): δ 170.52, 170.28, 170.11, 
169.75, 169.46, 166.56, 162.02, 132.17, 123.27, 122.83, 122.61, 122.24, 118.65, 104.42, 118.73, 
105.01, 104.42, 92.18, 72.28, 71.98, 68.71, 61.93, 52.02, 20.21, 43.06, 36.62, 36.44, 28.68, 
20.96, 20.88 (2C), 20.85 
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6-(Acetoxymethyl)-3-(3-(1-methyl-4-(1-methyl-4-(3-(methylsulfonyl)propanamido)-
1H-pyrrole-2-carboxamido)-1H-pyrrole carboxamido)propanamido)tetrahydro-2H-pyran-
2,4,5-triyl triacetate (18b).  Compound 18b  (0.383 g, 0.540 mmol) was dissolved in 50 mL of 
ethanol and 0.333 g 10 % water wet Pd/C was added in a Parr jar.  The mixture was shaken 
under pressurized hydrogen (70 psi) until 16b had disappeared by TLC (6:1 CHCl3/MeOH).  The 
Pd/C was filtered through celite and the filtrate was concentrated by rotary evaporation.  The 
residue was placed under high vacuum overnight.  The flask was flushed with N2 and the 
reduced compound 6 along with 3-(methylsulfonyl) propanoic acid (0.0824 g, 0.542 mmol), 
EDCI (0.160 g, 1.5 eq.), HOBT (0.218 g, 3.0 eq,), DMAP (0.166 g, 2.5 eq.) and CuCl2 (0.008 g, 
0.1 eq.) were dissolved in 3 mL of anhydrous DMF and allowed to stir at room temperature for 
two days until the disappearance of starting material as indicated by TLC (6:1 CHCl3/MeOH). 
The solution was diluted with 50 mL DCM and the organic solution was extracted with H2O (2 
x, 60 mL), 1 M HCl (2 x, 50 mL), and sat. NaHCO3 (2 x, 50 mL).  The organic layer was then 
dried over MgSO4.  The resulting solution was rotary evaporated until dry to yield the crude 
product.  The crude product was purified by flash column chromatography (6:1 CHCl3/MeOH) 
yield 18b as a brown solid (0.168 g, 40 %):  mp 94-97 oC.  TLC (6:1 CHCl3/MeOH) Rf = 0.40.  
1H NMR (D6-DMSO): δ 10.06 (s, 1H), 9.87 (s, 1H), 8.09 (d, J = 9.2 Hz, 1H), 7.95 (t, J = 8.4 Hz, 
1H), 7.16 (d, J = 1.2 Hz, 2H), 6.85 (d, J = 1.6 Hz, 1H), 6.79 (d, J = 1.6 Hz, 2H), 5.72 (d, J = 8.8 
Hz, 1H), 5.17 (t, J = 10.4 Hz, 1H), 4.88 (t, J = 10 Hz, 1H), 4.16 (dd, J = 8.4 Hz, 4 Hz, 1 H), 4.08 
(m, 3H), 3.80 (s, 3H), 3.77 (s, 3H), 3.01 (s, 3H), 2.30 (t, J = 7.2 Hz, 2H), 2.00 (s, 3H), 1.99 (s, 
3H), 1.96 (s, 3H), 1.87 (s, 3H).  13C NMR (D6-DMSO): δ 171.28, 170.76, 170.49, 170.06, 
169.73, 169.33, 166.55, 162.78, 161.69, 158.76, 123.29, 123.17, 122.49, 122.14, 118.63, 118.44, 
104.58, 104.34, 92.14, 72.62, 71.99, 61.95, 61.04, 52.33, 50.22, 49.63, 20.95, 20.86 (2C), 20.69. 
 80
6-(Acetoxymethyl)-3-(4-(1-methyl-4-(1-methyl-4-(3-(methylsulfonyl)propanamido)-
1H-pyrrole-2-carboxamido)-1H-pyrrole carboxamido)butanamido)tetrahydro-2H-pyran-
2,4,5-triyl triacetate (18c). Using the procedure described for 18a, 0.737 g, (1.0 mmol) of 16c, 
603 µL (3.6 mmol) of DIEA and 0.195 g of 3-(methylsulfonyl)propanoyl chloride to yield 18c as 
a brown solid (0.385 g, 46 %):  mp 154-160 oC.  TLC (4:1 EtOAc/MeOH) Rf = 0.63.  1H NMR 
data (D6-DMSO): δ 10.02 (s, 1H), 9.83 (s, 1H),  7.97 (t, J = 9.2 Hz, 1H), 7.14 (dd, J = 1.6 Hz, 2 
Hz, 2H), 6.83 (dd, J = 1.6 Hz, 6.4 Hz, 2H), 5.70 (d, J = 8.8 Hz, 1H), 5.15 (t, J = 9.6 Hz, 1H), 4.87 
(t, J = 9.6 Hz, 1H), 4.16 (dd, J = 8 Hz, 4Hz, 1H), 3.97 (m, 3H), 3.80 (s, 3H), 3.76 (s, 3H), 3.10 
(q, J = 6.4 Hz, 2H), 2.99 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.98 (s, 3H), 1.94 (s, 3H).  13C NMR 
data (D6-DMSO): δ 172.69, 170.50, 170.06, 169.73, 169.36, 166.54, 161.69, 158.76, 123.35, 
123.29, 122.44, 122.14, 118.62, 118.31, 104.62, 104.31, 92.19, 72.62, 71.97, 68.52, 52.25, 50.21, 
36.61, 36.40, 36.25, 33.72, 28.66, 26.16, 20.96, 20.87 (2C), 20.78. 
3-[N-(7’-Nitrobenz-2’-oxa-1’, 3’diazol-4’yl)amino]propanoic. (IUPAC: 2-(7-
nitrobenzo[c][1,2,5]oxodiazol-4-ylamino)acetic acid) (19).  Compound 19 was synthesized 
from 4-chloro-7-nitro-benzofurazane as described in literature.29  β-Alanine (6.24 g, 70 mmol, 
7eq.) and NaHCO3 (5.88 g, 70 mmol, 7eq) were dissolved in 20 mL of D.I water (20 mL).  After 
addition of 4-chloro-7-nitro-benzofurazane (2.0 g, 10 mmol) in methanol (80 mL) the mixture 
was stirred for 1.5 hours at 50 oC until TLC (4:1 CHCl3/MeOH) indicated disappearance of 
starting material.  The methanol was then removed by rotary evaporation leaving behind the 
water. The mixture was then cooled in an ice water bath while adjusting the pH to 1 with 1M 
HCl producing a brown precipitate.  The brown precipitate was then filtered to give pure 19 
(2.14 g, 90 %):  mp > 200 oC.  TLC 4:1 (CHCl3/MeOH) Rf = 0.20.  1H NMR data (D6-DMSO): δ 
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12.43 (s, 1H), 9.45 (s, 1H), 8.51 (d, J = 8 Hz, 1H), 6.44 (d, J = 8.8 Hz, 1H), 2.71 (t, J = 2.4 Hz, 
2H).  13C NMR (D6-DMSO): δ 172.87, 145.33, 144.84, 144.62, 138.38, 121.49, 99.86, 32.79. 
1-Methyl-4-(1-methyl-4-(2-(7-nitrobenzo[c][1,2,5,]oxodiazol-4-ylamino)acetamido-
1H-pyrrole-2-carboxamido N-propyl-1H-pyrrole-2-carboxamide (20).  Compound 6 (0.140 
g, 0.419 mmol) was dissolved in 50 mL of ethanol and of 0.1184 g 10 % water wet Pd/C was 
added in a Parr jar.  The mixture was shaken under pressurized hydrogen (70 psi) until 6 had 
disappeared by TLC (6:1 CHCl3/MeOH).  The Pd/C was filtered through celite and the filtrate 
was concentrated by rotary evaporation.  The residue was placed under high vacuum overnight.  
The flask was flushed with N2, the reduced compound 20 was dissolved in anhydrous DMF (3.5 
mL) along with carboxylic acid 19 (0.111 g, 0.466 mmol), EDCI (0.123 g, 1.5 eq.), DMAP 
(0.130 g, 2.5 eq.), HOBT (0.1750 g, 3eq), and CuCl2 (0.008g, 0.1 eq.).  The mixture was allowed 
to stir for two days until the disappearance of the starting material was indicated by TLC (6:1 
CHCl3/MeOH).  The solution was diluted with 100 mL DCM and the organic solution was 
extracted with H2O (2x, 150 mL), 1 M HCl (2x, 100 mL), and sat. NaHCO3 (2x, 100 mL).  The 
organic layer was then dried over MgSO4.  The resulting solution was rotary evaporated until dry 
to yield the crude product.  Flash column chromatography (6:1 CHCl3/MeOH) yielded pure 20 as 
an orange solid (0.067 g, 37%): mp 152-157 oC.  TLC (6:1 CHCl3/MeOH) Rf = 0.36.  1H NMR 
data (D6-DMSO): δ 9.99 (s, 1H), 9.83 (s, 1H), 9.52 (s, 1H), 8.54 (t, J = 8 Hz, 1H), 7.98 (t, J = 4 
Hz, 1H), 7.17 (d, J = 8 Hz, 2H), 6.84 (d, J = 8.4 Hz, 2H), 6.48 (d, J = 8.8 Hz, 2H), 3.82 (s, 3H), 
3.78 (s, 3H), 3.10 (d, J = 8 Hz, 2H), 2.72 (d, J = 6.8 Hz, 2H), 1.46 (m, 2H), 0.85 (t, J = 7.2 Hz, 
3H).  13C NMR (D6-DMSO): δ 167.45, 161.66, 158.76, 123.52, 123.25, 122.39, 122.13, 118.61, 
118.20, 104.54, 104.26, 41.67, 40.77, 36.61, 36.37, 23.04, 11.90. 
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6-(Acetoxymethyl)-3-(2-(1-methyl-4-(1-methyl-4-(2-(7-nitrobenzo[c][1,2,5]oxadiazol-
4-ylamino)acetamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido)acetamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate (21a).  Compound 13a 
(0.344 g, 0.495 mmol) was dissolved in 30 mL of ethanol and of 0.278 g 50 % water wet Pd/C 
was added in a Parr jar.  The mixture was shaken under pressurized hydrogen (60 psi) until 6 had 
disappeared by TLC (6:1 CHCl3/MeOH).  The Pd/C was filtered through celite and the filtrate 
was concentrated by rotary evaporation then further dried under high vacuum overnight.  The 
flask was flushed with N2, the reduced compound 13a was dissolved in anhydrous DMF (3mL) 
along with carboxylic acid 19 (0.118 g, 0.495 mmol), EDCI (0.147 g, 1.5 eq.), DMAP (0.151 g, 
2.5 eq.), HOBT (0.200 g, 3eq), and CuCl2 (0.009 g, 0.1 eq.).  The mixture was allowed to stir for 
two days until the disappearance of the starting material was indicated by TLC (6:1 
CHCl3/MeOH).  The solution was diluted with 150 mL DCM and the organic solution was 
extracted with H2O (2x, 200 mL), 1 M HCl (2x, 200 mL), and sat. NaHCO3 (2x, 200 mL).  The 
organic layer was then dried over MgSO4.  The resulting solution was rotary evaporated until dry 
to yield the crude product.  Flash column chromatography (6:1 CHCl3/MeOH) yielded pure 21a 
as an orange solid (0.200 g, 48%): mp 144 oC to decomp.  TLC (6:1 CHCl3/MeOH) Rf = 0.36.  
1H NMR data (D6-DMSO): δ 9.92 (s, 1H), 9.90 (s, 1H), 9.52 (s, 1H), 8.52 (t, J = 5.2 Hz, 1H), 
8.32 (t, J = 5.2 Hz, 1H), 7.82 (d, J = 9.6 Hz, 1H), 7.22 (s, 1H), 7.17 (d, J = 1.6 Hz, 1H), 6.87 (s, 
2H), 6.46 (d, J = 9.2 Hz, 1H), 5.74 (d, J = 8.8 Hz, 1H), 5.24 (t, J = 9.6 Hz, 1H), 4.85 (t, J = 9.6 
Hz, 1H), 4.18 (dd, J = 4.8 Hz, 8 Hz, 2H), 3.40 (m, 3H), 3.81 (s, 3H), 3.76 (s, 3H), 2.05 (s, 3H), 
1.99 (s, 3H), 1.95 (s, 3H), 1.94 (s, 3H).  13C NMR (D6-DMSO): δ 170.51, 170.27, 170.11, 
169.74, 169.45, 167.46, 162.01, 158.80, 132.16, 132.08, 129.1, 123.19, 122.82, 122.55, 122.24, 
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118.73, 104.96, 92.17, 72.28, 71.98, 68.72, 67.86, 61.94, 52.02, 36.63, 36.44, 30.25, 28.82, 
23.69, 22.87, 21.03, 20.96, 20.88, 20.85, 14.38, 11.27. 
6-(Acetoxymethyl)-3-(3-(1-methyl-4-(1-methyl-4-(2-(7-nitrobenzo[c][1,2,5]oxadiazol-
4-ylamino)acetamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido)propanamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate (21b).  Compound 
21b was synthesized similar to the procedure described above for 20a, reducing 0.4067 g (0.573 
mmol) of 15b to the amino and dissolving in 4 mL anhydrous DMF along with, compound 20 
(0.152 g, 0.64 mmol), EDCI (0.164 g, 1.5 eq.), DMAP (0.179 g, 2.5 eq.), HOBT (0.234 g, 3.0 
eq,), and CuCl2 (0.008 g, 0.1 eq.) to yield 21b as a dark brown solid (0.349 g, 68 %): mp TLC 
(6:1 CHCl3/MeOH) Rf = 0.27.  1H NMR data (D6-DMSO): δ 10.01 (s, 1H), 9.84 (s, 1H), 9.50 (s, 
1H), 8.50 (s, 1H), 8.07 (d, J = 8.8 Hz, 1H), 7.93 (t, J = 6 Hz, 1H), 7.13 (s, 1H), 6.83 (s, 1H), 6.75 
(s, 1H), 6.46 (d, J = 8.4 Hz, 1H), 5.68 (d, J = 8.8 Hz, 1H), 5.15 (t, J = 9.6 Hz, 1H), 4.85 (t, J = 10 
Hz, 1H), 4.15 (dd, J = 4.4 Hz, 9.2 Hz, 2H), 3.96 (m, 3H), 3.76 (s, 3H), 3.73 (s, 3H), 2.71 (q, J = 
6.8 Hz, 2H), 2.27 (t, J = 6.8 Hz, 2H), 1.95 (s, 6H), 1.92 (s, 3H), 1.83 (s, 3H).  13C NMR (D6-
DMSO): δ 171.21, 170.50, 170.06, 169.74, 169.34, 167.45, 161.68, 158.77, 145.44, 144.92, 
138.43, 123.20, 123.13, 12..49, 122.26, 118.62, 118.44, 104.58, 104.32, 99.93, 92.13, 72.61, 
71.96, 68.47, 61.93, 52.30, 36.62, 36.42, 36.03, 35.82, 20.97, 20.87, 20.70. 
6-(Acetoxymethyl)-3-(4-(1-methyl-4-(1-methyl-4-(2-(7-nitrobenzo[c][1,2,5]oxadiazol-
4-ylamino)acetamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido)butanamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate (21c).  Compound 21c 
was synthesized similar to the procedure described above for 20a, reducing 0.5424 g (0.751 
mmol) of 15c to the amino and dissolving in 4 mL anhydrous DMF along with, compound 20 
(0.197 g, 0.8 mmol), EDCI (0.213 g, 1.5 eq.), DMAP (0.243 g, 2.5 eq.), HOBT (0.307 g, 3.0 
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eq,), and CuCl2 (0.015 g, 0.1 eq.) to yield 21c as a dark brown solid (0.403 g, 60 %): mp TLC 
(6:1 CHCl3/MeOH) Rf = 0.38.  1H NMR data (D6-DMSO): δ 10.05 (s, 1H), 9.86 (s, 1H), 9.52 (s, 
1H), 8.55 (t, J = 5.6 Hz, 1H), 8.05 (t, J = 5.6 Hz, 1H), 7.16 (s, 2H), 6.86 (d, J = 6.6 Hz, 2H), 6.49 
(m, 1H), 5.72 (d, J = 8.45 Hz, 1H), 5.18 (t, J = 6 Hz, 1H), 4.88 (t, J = 6.4 Hz, 1H), 4.20 (dd, J = 
3.2 Hz, 6 Hz, 2H), 4.18 (t, J = 2 Hz, 3H), 3.83 (s, 3H), 3.79 (s, 3H), 3.12 (t, J = 2 Hz, 2H), 2.06 
(s, 3H), 2.02 (s, 3H), 1.98 (s, 3H), 1.93 (s, 3H), 1.65 (pentet, J = 1.2 Hz, 4.8 Hz, 2H).  13C NMR 
(D6-DMSO): δ172.70, 170.50, 170.05, 169.74, 169.36, 167.45, 162.78, 161.67, 158.76, 144.84, 
144.55, 138.38, 123.20, 122.42, 122.24, 118.61, 118.29, 104.60, 104.25, 99.88, 92.17, 72.61, 
71.95, 68.48, 61.90, 60.68, 52.22, 38.35, 36.61, 36.40, 36.24, 33.71, 31.22, 26.16, 20.95, 20.86, 
20.77. 
Methyl 4-(4-acrylamido-1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-
pyrrole-2-carboxylate (22).  Compound 7 (4.10 g, 19.6 mmol) was dissolved in 50 mL of EtOH 
and 0.50 g 10 % water wet Pd/C was added in a parr jar.  The mixture was shaken under 
pressurized hydrogen (70 psi) until 7 had disappeared as indicated by TLC (EtOAc).  The Pd/C 
was filtered through celite and the filtrate was concentrated by rotary evaporation and the residue 
was kept under high vacuum overnight.  The flask with the residue was flushed with Ar and the 
residue was dissolved in anhydrous THF (8 mL) and anhydrous DIEA (3.32 mL) was added to 
the solution.  The solution was bubbled with Ar and cooled to -40 oC.  Acryloyl chloride (1.20 
mL) was added drop wise to the solution which was then allowed to stir at -20 oC, protected from 
light, until the reaction was complete as indicated by TLC (6:1 CHCl3/MeOH).  The solvent was 
removed by rotary evaporation and the resulting solid dissolved in 50 mL of EtOAc and 
extracted with DI H2O (2x, 60 mL).  The organic layer was then dried over MgSO4.  The 
resulting solution was rotary evaporated until dry to yield the product, 22 as an orange solid 
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(4.18 g, 96 %): mp 179-184 oC. TLC (6:1 CHCl3/MeOH) Rf = 0.58.  1H NMR data (D6-DMSO): 
δ 10.11 (s, 1H), 9.93 (s, 1H), 7.44 (d, J = 1.6 Hz, 1H), 7.25 (d, J = 1.6 Hz, 1H), 6.90 (d, J = 2.0 
Hz, 1H), 6.87 (d, J = 2.4 Hz, 1H), 6.33 (m, 1H), 6.16 (dd, J = 2.0 Hz, 15.2 Hz, 1H), 5.65 (dd, J = 
2.0 Hz, 8 Hz, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 3.72 (s, 3H).  13C NMR (D6-DMSO): δ 162.10, 
161.26, 158.77, 131.91, 126.10, 125.70, 123.29, 122.21, 121.22, 119.03, 118.97, 108.77, 104.54, 
51.44, 36.62 (2C). 
3-(5-(5-(Methoxycarbonyl)-1-methyl-1H-pyrrol-3-ylcarbamoyl)-1-methyl-1H-
pyrrol-3-ylamino)-3-oxopropane-1-sulfonic acid (23).  To a solution of alkene 22 (1.68 g, 5.1 
mmol) dissolved in 4 mL EtOH, NaHSO3 (1.06 g, 10 mmol) dissolved in 1mL of DI H2O was 
added all at once.  The pH was adjusted to 8 with 5 % NaOH and the mixture was refluxed until 
22 had disappeared and a baseline spot appeared by TLC (6:1 CHCl3/MeOH).  The solution was 
then rotovaped until a minimal amount of water remained.  This solution was then cooled in an 
ice/water bath and the pH adjusted to 1 with concentrated HCl.  A pale yellow precipitate fell out 
of solution, which was vacuum filtered to give pure 23 as a pale yellow solid (2.10 g, 81 %): mp 
decomposition 197 oC. TLC (5:2 CHCl3/MeOH) Rf = 0.27.  1H NMR data (D6-DMSO): δ 9.97 
(s, 1H), 9.89 (s, 1H), 7.44 (s, 1H), 7.14 (s, 1H), 6.88 (s, 1H), 6.84 (s, 1H), 3.82 (s, 3H), 3.80 (s, 
3H), 3.72 (s,  3H), 2.64 (d, J = 8.4 Hz, 2H), 2.54 (d, J = 8.8 Hz, 2H).  13C NMR (D6-DMSO): δ 
169.02, 161.28, 158.89, 123.40, 122.89, 121.21, 118.97, 118.74, 51.41, 48.03, 36.62, 36.50, 
33.00, 31.16. 
1-Methyl-4-(1-methyl-4-(3-sulfopropanamido)-1H-pyrrole-2-carboxamido)-1H-
pyrrole-2-carboxylic acid (24).  To a solution of sulfonic acid 23 (33 mg, 79 µmol) suspended 
in 4 mL of EtOH, NaOH (19 mg, 4.8 mmol) dissolved in 1 mL of DI H2O was added all at once.  
The mixture was refluxed until 23 had disappeared and a baseline spot appeared by TLC (6:1 
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CHCl3/MeOH).  The solution was then rotovaped until a minimal amount of water remained.  
This solution was then cooled in an ice/water bath and the pH adjusted to 1 with concentrated 
HCl.  A pale yellow precipitate fell out of solution, which was vacuum filtered to give pure 24 as 
a pale yellow solid (25 mg, 72 %): mp decomposition 169 oC.  TLC 3:1 CHCl3/MeOH Rf = 0.20. 
1H NMR data (D6-DMSO): δ 9.95 (s, 1H), 9.70 (s, 1H), 7.11 (d, J = 2.0 Hz, 1H), 7.07 (d, J = 1.6 
Hz, 1H), 6.80 (d, J = 1.6 Hz, 1H), 6.50 (d, J = 1.6 Hz, 1H), 6.04 (s, 1H), 3.79 (s, 3H), 3.77 (s, 
3H), 2.66 (d, J = 8.8 Hz, 2H), 2.52 (d, J = 7.2 Hz, 2H).  13C NMR (D6-DMSO): δ 168.57, 
158.42, 123.89, 123.47, 122.40, 119.63, 118.24, 112.25, 104.02, 101.01, 47.95, 36.47, 36.30, 
32.55. 
Ethyl 3-(1-methyl-4-(1-methyl-4-(3-(methylsulfonyl)propanamido)-1H-pyrrole-2-
carboxamido)1H-pyrrole-2-carboxamido)propanoate (25).  Compound 5b (1.03 g, 2.65 
mmol) was dissolved in 50 mL of ethanol and 0.500 g 50 % water wet Pd/C was added in a Parr 
jar.  The mixture was shaken under pressurized hydrogen (70 psi) until 5b had disappeared by 
TLC (EtOAc).  The Pd/C was filtered through celite and the filtrate was concentrated by rotary 
evaporation.  The residue was placed under high vacuum overnight.  The 3-(methylsulfonyl) 
propanoic acid (0.500 g, 3.3 mmol) was dissolved in 4 mL of anhydrous DMF along with, EDCI 
(0.785 g, 1.5 eq.), DMAP (0.818 g, 2.5 eq.), HOBT (1.11 g, 3.0 eq,), and CuCl2 (0.042 g, 0.1 
eq.).  After stirring for 1 hour the reduced compound 5b was canulated into the mixture and 
stirred at room temperature for two days until the disappearance of starting material as indicated 
by TLC (6:1 CHCl3/MeOH).  The solution was diluted with 100 mL of DCM and the organic 
solution was extracted with H2O (2x, 200 mL), sat. NaHCO3 (2x, 200 mL), and 1 M HCl (2x, 
200 mL).  The organic layer was then dried over MgSO4.  The resulting solution was rotary 
evaporated until dry to yield a red-brown solid 17 (0.052g, 40%): mp 75-80 oC.  TLC (6:1 
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CHCl3/MeOH) Rf = 0.64. 1H NMR data (D6-DMSO): δ 10.06 (s, 1H), 9.87 (s, 1H), 8.05 (t, J = 
Hz, 1H), 7.16 (d, J = 8 Hz, 2H), 6.85 (d, J = Hz, 2H), 4.04 (q, J = 6.8 Hz, 7.2 Hz, 3H), 3.81 (s, 
3H), 3.78 (s, 3H), 3.00 (s, 3H), 2.72 (t, J = 8 Hz, 2H), 1.17 (t, J = 7.2 Hz, 3H). 13C NMR data 
(D6-DMSO): δ 171.84, 170.76, 161.74, 158.76, 123.14, 122.49, 122.14, 118.63, 118.44, 104.73, 
104.33, 61.03, 60.34, 49.63, 36.40, 35.26, 34.49, 27.58, 14.55, 14.47. 
(2S,3R,4R,5S,6R)-6-(Acetoxymethyl)-3-benzamidotetrahydro-2H-pyran-2,4,5-triyl 
triacetate (26).  Compound 12 (4.12 g, 11 mmol) was suspended in 100 mL of DCM.  While 
vigorously stirring the solution was cooled to 0 oC in an ice cold water bath. Saturated NaHCO3 
(100 mL) was added to the cooled solution making a heterogeneous system.  Benzoyl chloride (2 
mL, 17 mmol) mixed with DCM (10 mL) was added to the heterogeneous solution drop wise in a 
drop funnel.  After 45 minutes of stirring at 0 oC a white precipitate formed, the reaction was 
allowed to reach room temperature before filtering the pure white solid 26 (2.78 g, 56 %): mp > 
200 oC.  TLC (6:1 CHCl3/MeOH) Rf = 0.67.  1H NMR data (D6-DMSO): δ 8.56 (d, J = 9.2 Hz, 
1H), 7.71 (dd, J = 1.2 Hz, 8 Hz, 2H), 7.50 (m, 3H), 5.88 (d, J = 8.8 Hz, 1H), 5.34 (t, J = 9.6 Hz, 
1H), 4.97 (t, J = 9.6 Hz, 1H), 4.22 (m, 3H), 2.02 (s, 3H), 2.00 (s, 3H), 1.98 (s, 3H), 1.85 (s,3H).  
13 C NMR data (D6-DMSO) δ: 170.54, 170.13, 169.76, 169.35, 167.06, 134.52, 132.01, 128.92, 
127.54, 92.32, 72.83, 72.14, 68.39, 61.93, 53.01, 20.99, 20.95, 20.89, 20.72. 
N-((2R,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-
yl)benzamide (27).   Compound 27 was deacetylated using a combo of procedures from 
literature.30,31  Compound 26 (0.052 g, 0.12 mmol) was dissolved in 1.1 mL of dry THF and 
cooled to -10 oC.  Freshly prepared 1 M NaOCH3 (416 μL, 0.461 mmol) was added to the cooled 
solution and deprotection was monitored by TLC (6:1CHCl3/MeOH) until reaction was complete 
in 20 minutes.  The mixture was treated with Dowex 50WA resin, filtered, and the solvent 
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removed by rotary evaporation to give 27 as a white solid (0.029 g, 91 %, 4:1 diasteromers): mp 
159-163 oC. TLC (3:1 CHCl3/MeOH) Rf = 0.34.  1H NMR data (D6-DMSO): δ 8.17 (d, J = 8.9 
Hz, 1H), 8.03 (d, J = 7.2 Hz, 1H), 7.87 (m, 4H), 7.49 (m, 6H), 6.55 (d, J = 6 Hz, 1H), 6.45 (d, J = 
4.4 Hz, 1H), 5.07 (t, J = 4 Hz, 1H), 4.96 (d, J = 5.2 Hz, 1H), 4.70 (d, J = 5.2 Hz, 1H), 4.46 (t, J = 
5.9 Hz, 1H), 3.74 (m, 3H), 3.62 (m, 3 H), 3.51 (m, 1H).  13 C NMR data (D6-DMSO) δ: 166.88, 
134.95, 131.57, 128.59, 127.92, 127.78, 90.87, 72.61, 71.46, 70.49, 61.58, 55.83. 
1-Methyl-4-(1-methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-
2-carboxamido)-N-propyl-1H-pyrrole-2-carboxamide (28).  Compound 28 was synthesized as 
described in literature.32  Compound 6 (0.359 g, 1.1 mmol) was dissolved in 50 mL of EtOH and 
0.340 g 50 % water wet Pd/C was added in a parr jar.  The mixture was shaken under pressurized 
hydrogen (70 psi) until 6 had disappeared as indicated by TLC (6:1CHCl3/MeOH).  The Pd/C 
was filtered through celite and the filtrate was concentrated by rotary evaporation to yield 0.330 
g (0.99 mmol) of reduced compound 6 and stored under high vacuum overnight.  Compound 2 
was added to a solution of reduced compound 6 (0.330 g, 0.99 mmol) dissolved in anhydrous 
acetonitrile at 0 oC.  The mixture was then allowed to reach room temperature and stir for two 
days or until TLC (EtOAc) indicated the disappearance of both starting compounds.  The solvent 
was evaporated under rotary evaporation and the brown residue was recrystallized from 
methanol to afford 0.138 g (28%) of 28 as a yellow powder: mp > 200 oC. TLC (EtOAc) Rf = 
0.36.  1H NMR data (D6-DMSO): δ 10.29 (s, 1H), 9.94 (s, 1H), 8.19 (d, J = 1.6 Hz, 1H), 8.00 (t, 
J = 5.6, 1H), 7.58 (d, J = 1.2 Hz, 1H), 7.26 (d, J = 1.6 Hz, 1H), 7.17 (d, J = 1.6 Hz, 1H), 7.02 (d, 
J = 1.6 Hz, 1H), 6.84 (d, J = 2.0 Hz, 1H), 3.95 (s, 3H), 3.85 (s, 3H), 3.78 (s, 3H), 3.10 (m, 2H), 
1.47 (m, 2H), 0.85 (t, J = 7.2 Hz, 3H).  13C NMR data (D6-DMSO): δ 161.67, 158.77, 157.36, 
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134.24, 128.74, 126.75, 123.49, 122.45, 121.86, 119.04, 118.20, 108.06, 104.89, 104.54, 79.44, 
37.97, 36.67, 23.07, 11.92. 
6-(Acetoxymethyl)-2-(3-(4-(4-(3-(tert-butoxycarbonylamino)propanamido)-1-
methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-
carboxamido)propanamido)tetrahydro-2H-pyran-2,4,5-tryl triacetate (29).  Compound 13b 
(0.313 g, 0.44 mmol) was dissolved in 30 mL of EtOH and 0.200 g 50 % water wet Pd/C was 
added in a parr jar.  The mixture was shaken under pressurized hydrogen (70 psi) until 13b had 
disappeared as indicated by TLC (6:1CHCl3/MeOH).  The Pd/C was filtered through celite and 
the filtrate was concentrated by rotary evaporation and the reduced compound 13b was stored 
under high vacuum overnight.  The reduced compound 13b and N-Boc-beta-alanine (0.170 g, 
0.89 mmol) was dissolved in 3 mL of anhydrous DMF along with, EDCI (0.143 g, 1.5 eq.), 
DMAP (0.140 g, 2.5 eq.), HOBT (0.179 g, 3.0 eq,), and CuCl2 (0.005 g, 0.1 eq.).  The mixture 
was allowed to stir for two days until the disappearance of starting material as indicated by TLC 
(6:1 CHCl3/MeOH).  The solution was diluted with 100 mL of DCM and the organic solution 
was extracted with H2O (2x, 100 mL), sat. NaHCO3 (2x, 100 mL), and 1 M HCl (2x, 100 mL).  
The organic layer was then dried over MgSO4.  The resulting solution was rotary evaporated 
until dry to yield a red-brown solid 29 (0.211 g, 57%): mp 106-110 oC.  TLC (6:1 CHCl3/MeOH) 
Rf = 0.65. 1H NMR data (D6-DMSO): δ. 9.87 (s, 1H), 8.10 (d, J = 8.8 Hz, 2H), 7.19 (dd, J = 1.6 
Hz, 10.4 Hz, 2H), 6.83 (dd, J = 1.6 Hz, 9.2 Hz, 2H), 5.74 (d, J = 9.2 Hz, 1H), 5.20 (t, J = 9.2 Hz, 
1H), 4.90 (t, J = 9.2 Hz, 1H), 4.19 (dd, J = 4.4 Hz, 8 Hz, 2H), 4.01 (m, 3H), 3.83 (s, 3H), 3.80 (s, 
3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.98 (s, 3H), 1.89 (s, 3H), 1.39 (s, 9H).  13C NMR data (D6-
DMSO): δ171.28, 171.02, 170.47, 170.05, 169.71, 169.30, 161.65, 158.52, 124.90, 123.33, 
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122.26, 119.58, 118.42, 113.11, 104.53 (2C), 92.15, 72.63, 72.00, 68.52, 61.96, 52.36, 36.99, 
36.43, 28.67, 21.08, 20.95, 20.86, 20.69. 
Tert-butyl 3-(1-methyl-5-(1-methyl-5-(propylcarbamoyl)-1H-pyrrole-3-
ylcarbamoyl)-1H-pyrrole-3-ylamino)3-oxopropylcarbamate (30).  Compound 30 was 
synthesized using a procedure similar to the one described for 29 using 0.2110 g (0.633 mmol) of 
6, 3 mL anhydrous DMF along with, EDCI (0.190 g, 1.5 eq.), DMAP (0.194 g, 2.5 eq.), HOBT 
(0.258 g, 3.0 eq,), CuCl2 (0.01 g, 0.1 eq.) and 0.121 g (0.633 mmol) N-Boc-beta-alanine to yield 
30 as a red-brown solid (0.227 g, 74 %): mp 171-176 oC. TLC (6:1 CHCl3/MeOH) Rf = 0.53.  1H 
NMR (D6-DMSO): δ 9.84 (d, J = 4.8 Hz, 1H), 7.97 (t, J = 5.6 Hz, 1H), 7.15 (t, J =  1.6 Hz, 2H), 
6.83 (dd, J = 1.6 Hz, 4 Hz, 3H), 3.81 (s, 3H), 3.78 (s, 3H), 3.14 (m, 4H), 2.49 (q, J = 6 Hz, 6.8 
Hz, 2H), 1.47 (m, 2H), 1.36 (s, 10 H), 0.86 (t, J = 7.2 Hz, 3H). 13C NMR (D6-DMSO) δ: 171.62, 
168.05, 161.69, 158.82, 123.55, 123.21, 122.46, 122.38, 18.58, 118.18, 204.57, 104.34, 78.08, 
60.31, 36.54, 36.35, 28.71, 23.04, 14.52, 11.89. 
Ethyl 3-(2-oxo-2H-3-carboxamido)propanoate (31).  In a flask flushed with Ar, 
coumarin-3-carboxylic acid (0.503 g, 0.26 mmol) was dissolved in 4 mL of DMF along with 
EDCI (0.774 g, 1.5 eq.), DMAP (0.799 g, 2.5 eq.), HOBT (1.06 g, 3.0 eq,), CuCl2 (0.037 g, 0.1 
eq.), and β-Alanine ethyl ester hydrochloride (0.413 g, 0.27 mmol).  The reaction was allowed to 
stir for two days until TLC (3:1 EtOAc/MeOH) indicated the disappearance of starting 
carboxylic acid.  The mixture was diluted with 100 mL of DCM and the organic solution was 
extracted with H2O (2x, 100 mL), sat. NaHCO3 (2x, 100 mL), and 1 M HCl (2x, 100 mL).  The 
organic layer was then dried over MgSO4.  The resulting solution was rotary evaporated until dry 
to yield a white solid 29 (0.607 g, 80%): mp 116-118 oC.  TLC (3:1 EtOAc/MeOH) Rf = 0.67.  
1H NMR (D6-DMSO): δ 8.88 (s, 2H), 7.98 (d, J = 8 Hz, 1H), 7.74 (t, J = 7.6 Hz, 1H), 7.50 (d, J 
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= 8 Hz, 1H), 7.44 (t, J = 7.6 Hz, 1H), 4.08 (q, J = 6.8 Hz, 7.2 Hz, 2H), 3.56 (q, J = 6.4 Hz, 6 Hz, 
2H), 2.58 (t, J = 2.4 Hz, 3H), 1.19 (t, J = 7.2 Hz, 3H).  13C NMR (D6-DMSO): δ 171.92, 161.54, 
160.82, 154.37, 148.16, 134.61, 130.78, 125.60, 119.90, 118.91, 116.59, 60.56, 35.54, 34.13, 
14.52.  
3-(2-Oxo-2H-chromene-3-carboxamido)propanoic acid (32).  To a solution of ester 31 
(0.493 g, 1.7 mmol) suspended in 12 mL of acetonitrile, NaOH (0.277 g, 6.9 mmol) dissolved in 
3 mL of DI H2O was added all at once.  The mixture was stirred at room temperature until 31 
had disappeared and a baseline spot appeared by TLC (3:1 EtOAc/MeOH).  The solution was 
then rotary evaporated until a minimal amount of water remained.  This solution was then cooled 
in an ice/water bath and the pH adjusted to 1 with concentrated HCl.  A white precipitate fell out 
of solution, which was vacuum filtered to give pure 32 as a white solid (0.397 g, 88 %): mp 204-
206 oC.  TLC (3:1 EtOAc/MeOH) Rf  = 0.73.  1H NMR data (D6-DMSO): δ 12.36 (s, 1H), 8.88 
(s, 2H), 7.98 (d, J = 8 Hz, 1H), 7.74 (t, J = 7.6 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1H), 7.43 (t, J = 7.6 
Hz, 1H), 3.52 (d, J = 6.4 Hz, 2H).  13C NMR (D6-DMSO): δ 173.58, 161.44, 160.85, 154.34, 
148.12, 134.56, 130.75, 125.57, 119.06, 118.90, 116.57, 35.56, 34.14. 
Ethyl 3-(7-nitrobenzo[c][1,2,5]oxadiazol-4-ylamino)propanoate (33).  In a flask 
flushed with Ar, 4-chloro-7-nitro-2,1,3-benzoxadiazole (0.102 g, 0.50 mmol) and β-Alanine 
ethyl ester hydrochloride (0.085 g, 0.51 mmol) were dissolved in 2 mL of EtOAc dried over 
sieves.  To this mixture TEA (175 μL, 0.13 mmol, 2.5 eq.) dried over sieves was added causing 
the color of the reaction to change from yellow to orange.  The reaction was monitored by TLC 
(3:1 EtOAc/MeOH) until complete disappearance of 4-chloro-7-nitro-2,1,3-benzoxadiazole.  The 
solution was rotary evaporated to dryness and then dissolved in 50 mL of DCM and the organic 
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solution was extracted with 1M HCl (2x, 60 mL).  The organic layer was then dried over MgSO4.  
The resulting solution was rotary evaporated until dry to yield a red-brown solid 33 (0.163 g, 
87 %):  mp decomposition at 170 oC.  TLC (3:1 EtOAc/MeOH) Rf = 0.65.  1H NMR data (D6-
DMSO): δ 9.43 (s, 1H), 8.52 (d, J = 8.4 Hz, 1H), 6.43 (d, J = 8.8 Hz, 1H), 4.05 (q, J = 7.2 Hz, 
2H), 3.67 (s, 2H), 2.75 (t, 6.8 Hz, 2H), 1.15 (t, J = 7.2 Hz, 3H).  13C NMR (D6-DMSO): δ 
171.29, 145.23, 144.76, 144.20, 138.27, 121.46, 99.85, 60.67, 14.50. 
N-(2-bromoethyl)-1-mthyl-4-nitro-1H-pyrrole-2-carboxamide (34).   Compound 2 
(4.92 g, 18 mmol) was dissolved in 40 mL of EtOAc dried over sieves.  2-bromoethylamine 
hydrobromide (9.28 g, 45 mmol) was then added to solution resulting in a suspension.  TEA 
(7.53 mL, 54 mmol) dissolved in 10 mL of EtOAc dried over sieves was added drop wise to the 
mixture via a drop funnel.  The mixture stirred for two days at which time a brown precipitate 
formed.  The precipitate was filtered and the filtrate extracted with 1M HCl (2x, 60 mL) and DI 
H2O (2x, 60 mL).  The organic layer was then dried over MgSO4.  The resulting solution was 
rotary evaporated until dry to yield a pale orange solid 34 (3.23 g, 64 %): mp 130-135 oC.  TLC 
(6:1 CHCl3/MeOH) Rf = 0.52.  1H NMR data (D6-DMSO): δ 8.69 (s, 1H), 8.14 (d, J = 1.6 Hz, 
1H), 7.44 (d, J = 2 Hz, 1H), 3.89 (s, 3H).  13C NMR (D6-DMSO): δ 160.38, 134.24, 128.60, 
162.40, 108.10, 41.15, 37.90, 32.46.  1H NMR data (CDCl3): δ 7.58 (d, J = 1.6 Hz, 1H), 7.14 (d, 
J = 1.6 Hz, 1H), 6.40 (s, 1H), 3.99 (s, 3H), 3.80 (q, J = 6 Hz, 5.6 Hz, 2H), 3.56 (t, J = 5.6 Hz, 
2H).  13C NMR (D6-DMSO): δ 160.32, 135.00, 126.95, 125.80, 107.36, 41.03, 37.95, 32.13. 
6-(Acetoxymethyl)-3-(3-(1-methyl-4-propionamido-1H-pyrrole-2-carboxamido)-1H-
pyrrole-2-carboxamido)propanamido)tetrahydro-2H-pyran-2,4,5-tryl triacetate (35a). 
Compound 16b (0.110 g, 0.15 mmol) was dissolved in 20 mL of 200 proof EtOH and 0.200 g 50 
% water wet Pd/C was added in a parr jar.  The mixture was shaken under pressurized hydrogen 
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(80 psi) until 16b had disappeared as indicated by TLC (6:1CHCl3/MeOH).  The Pd/C was 
filtered through celite and the filtrate was concentrated by rotary evaporation to yield pure 35a as 
a white solid (0.108g, 98 %): mp 141-148 oC.  TLC (6:1CHCl3/MeOH) Rf = 0.47.  1H NMR data 
(D6-DMSO): δ 9.85 (s, 1H), 9.75 (s, 1H), 8.09 (d, J = 9.2 Hz, 1H), 7.96 (t, J = 6.0 Hz, 1H), 7.17 
(dd, J = 1.2 Hz, 13.2 Hz, 2H), 6.82 (dd, J = 1.6 Hz, 14.8 Hz, 2H), 5.72 (d, J = 1.2 Hz, 1H), 5.18 
(t, J = 10 Hz, 1H), 4.88 (t, J = 10 Hz, 1H), 4.20 (dd, J = 4.4 Hz, 8.0 Hz, 1H), 3.98 (m, 3H), 3.81 
(s, 3H), 3.78 (s, 3H), 2.30 (t, J = 7.2 Hz, 2H), 2.24 (q, J = 7.6 Hz, 2H), 2.001 (s, 3H), 1.99 (s, 
3H), 1.97 (s, 3H), 1.88 (s, 3H), 1.05 (t, J = 7.2 Hz, 3H).  13C NMR (D6-DMSO): δ 171.27, 
170.72, 170.50, 170.07, 169.74, 169.34, 161.69, 158.83, 123.12, 122.54, 118.52, 118.42, 104.56, 
104.38, 92.13, 72.61, 71.96, 68.47, 61.93, 52.31, 36.54, 36.41, 36.04, 35.81, 29.21, 20.97, 20.87, 
20.70, 10.48. 
6-(Acetoxymethyl)-3-(4-(1-methyl-4-propionamido-1H-pyrrole-2-carboxamido)-1H-
pyrrole-2-carboxamido)butanamido)tetrahydro-2H-pyran-2,4,5-tryl triacetate (35b).  
Compound 35b was synthesized similar to the procedure described above for 35a, using 0.100 g 
(0.13 mmol) of 16c and 0.100 g of 50 % water wet Pd/C to yield pure 35b as a white solid (0.087 
g, 87 %):  mp 141-147 oC.  TLC (6:1CHCl3/MeOH) Rf  = 0.44.  1H NMR data (D6-DMSO): δ 
9.84 (s, 1H), 9.75 (s, 1H), 8.01 (m, 2H), 7.16 (d, J = 8.8 Hz, 2H), 6.84 (s, 2H), 5.71 (d, J = 8.8 
Hz, 1H), 5.17 (t, J = 10 Hz, 1H), 4.90 (t, J = 10 Hz, 1H), 4.18 (dd, J = 4.8 Hz, 8 Hz, 1H), 3.99 
(m, 3H), 3.81 (s, 3H), 3.78 (s, 3H), 3.43 (m, 2H), 3.11 (q, J = 6 Hz, 2H), 2.22 (q, J = 7.6 Hz, 2H), 
2.05 (s, 3H), 2.00 (s, 3H), 1.97 (s, 3H), 1.92 (s, 3H), 1.65 (t, J = 7.2 Hz, 2H), 1.06 (t, J = 7.2 Hz, 
3H).  13C NMR (D6-DMSO): δ 172.71, 170.76, 170.48, 170.04, 169.72, 169.33, 161.72, 158.88, 
123.37, 123.18, 122.57, 118.54, 118.31, 104.66, 104.43, 92.22, 72.66, 72.00, 68.57, 52.30, 38.41, 
36.52, 36.38, 33.74, 29.22, 26.18, 20.95, 20.85, 20.77, 10.46. 
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1-Methyl-4-propionamido-1H-pyrrole-2-carboxamido)-N-(3-oxo-3-(2,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-ylamino)propyl)-1H-pyrrole-2-
carboxamide (36).  Compound 35a (0.055 g, 0.077 mmol) was deacetylated with anhydrous 7N 
methanolic ammonia (3mL).  The reaction was monitored by TLC (6:1CHCl3/MeOH) until 
compound 35a condensed to a baseline spot.  Once a baseline spot, the solvent system was 
changed to 100 % MeOH to ensure complete deprotection if the acetyl groups.  When complete 
by TLC (MeOH) the mixture was rotovaped to dryness and placed under vacuum to yield crude 
35a.  The crude compound was then recrytallized in EtOH to yield 36 as a white solid (0.10 g, 24 
%, mixture of diasteromers 2:1): mp 215-219 oC.  TLC (3:2 CHCl3/MeOH) Rf = 0.57. 1H NMR 
data (D6-DMSO): δ 9.85 (s, 1H), 9.75 (s, 1H), 8.09 (d, J = 9.2 Hz, 1H), 7.96 (t, J = 5.2 Hz, 1H), 
7.79 (d, J = 7.8 Hz, 1H, minor) 7.75 (d, J = 8.8 Hz, 1H, major), 7.18 (d, J = 16 Hz, 2H), 6.83 (d, J 
= 14 Hz, 2H), 6.51 (d, J = 6 Hz, 1H, major), 6.42 (d, J = 4.4 Hz, 1H, minor), 4.89 (m, 2H), 4.84 
(d, J = 4 Hz, 1H, minor),  4.62 (d, J = 5.2 Hz, 1H, major).  13C NMR (D6-DMSO): δ 171.3, 
170.9, 161.6, 158.7, 123.29, 123.12, 122.58, 121.75, 118.54, 118.36, 104.54, 104.37, 91.04, 
72.57, 71.60, 70.93, 61.60, 54.73, 36.57, 36.42, 35.81, 29.21, 10.29. 
Ethyl 4-(4-(4-(3-bromopropanamido)1-methyl-1H-pyrrole-2-carboxamido)-1-
methyl-1H-pyrrole-2-carboxamido)butanoate (37).  Compound 5c (0.203 g, 0.501 mmol) was 
dissolved in 50 mL of EtOH and 0.250 g 50 % water wet Pd/C was added in a parr jar.  The 
mixture was shaken under pressurized hydrogen (70 psi) until 5c had disappeared as indicated by 
TLC (6:1CHCl3/MeOH).  The Pd/C was filtered through celite and the filtrate was concentrated 
by rotary evaporation and the reduced compound 5c was stored under high vacuum overnight.  
The reduced compound 5c was dissolved in DCM (15 mL) and cooled to 0 oC in an ice/water 
bath.  Saturated NaHCO3 (15 mL) was added to forma two-phase system, while stirring 
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vigorously.  3-Bromopropionyl chloride (38 μL, 0.37 mmol) was dissolved in DCM (5 mL) and 
added drop wise via a drop funnel for over 5 minutes.  The mixture stirred vigorously for 30 
minutes at 0 oC then allowed to stir at room temperature for 2 hours.  When the reaction was 
complete by TLC (6:1CHCl3/MeOH) the organic layer was removed by transferring the solution 
to a separatory funnel.  The organic layer was then dried with MgSO4, filtered, and rotary 
evaporated to dryness to yield a pure brown solid 37 (0.221 g, 84 %): mp 75-79 oC.  TLC 
(6:1CHCl3/MeOH) Rf = 0.64. 1H NMR data (D6-DMSO): δ 10.09 (s, 1H), 9.89 (s, 1H), 8.03 (t, J 
= 6 Hz, 1H), 7.18 (s, 2H), 6.86 (d, J = 11.2 Hz, 2H),  4.06(q, J = 6.8 Hz, 7.2 Hz, 2H), 3.83 (s, 
3H), 3.79 (s, 3H), 3.74 (t, J= 6.4 Hz, 2H), 3.18 (t, J = 5.6 Hz, 2H), 2.88 (t, J = 6.4 Hz, 1H), 2.32 
(t, J = 7.2 Hz, 2H), 1.73 (t, J = 6.8 Hz, 3H), 1.20 (m, 2H).  13C NMR (D6-DMSO): δ 173.18, 
166.84, 166.62, 161.76, 158.78, 12.32, 123.27, 122.48, 122.15, 118.65, 118.30, 104.64, 104.37, 
60.22, 38.16, 36.58, 36.41, 31.50, 30.14, 25.17, 14.56. 
3-(5-(5-(4-Ethoxy-4-oxobutylcarbamoyl)-1-methyl-1H-pyrrol-3-ylcarbamoyl)-1-
methyl-1H-pyrrol-3-ylamino)-3-oxopropane-1-sulfonic acid (38).  To a solution of compound 
37 (0.093 g, 0.18 mmol) dissolved in 4 mL EtOH, 15 % aqueous Na2SO3 (4mL) was added and 
the mixture refluxed until 37 disappeared and a baseline spot appeared by TLC (6:1 
CHCl3/MeOH).  The solvent was then removed by rotary evaporation until a minimal amount of 
water remained.  This solution was then cooled in an ice/water bath and the pH adjusted to 1 
with concentrated HCl.  A brown precipitate fell out of solution, which was vacuum filtered to 
give pure 38 as a brown solid (0.087 g, 94 %): mp 165-170 oC. TLC (5:2 CHCl3/MeOH) Rf = 
0.32.  1H NMR data (D6-DMSO): δ 9.94 (s, 1H0, 9.82 (s, 1H), 8.00 (t, J = 5.6 Hz, 1H), 7.15 (d, J 
= 10 Hz, 2H), 6.82 (s, 2H), 4.02 (q, J = 7.2 Hz, 2H), 3.78 (s, 3H), 3.76 (s, 3H), 2.69 (t, J = 7.2 
Hz, 2H), 2.58 (t, J = 8.4 Hz, 2H), 2.22 (t, J = 7.2 Hz, 2H), 1.69 (pentet, J = 3.6 Hz, 7.2 Hz, 6.8 
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Hz, 2H), 1.17 (t, J = 7.2 Hz, 3H).  13C NMR (D6-DMSO): δ 173.28, 168.96, 161.76, 158.81, 
123.28, 123.08, 122.54, 118.55, 118.25, 104.61, 104.32, 60.21, 48.03, 38.15, 36.54, 36.39, 32.98, 
31.50, 25.16, 14.58 
6-(Acetoxymethyl)-3-(3-(4-(4-(3-bromopropanamido)-1-methyl-1H-pyrrole-2-
carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)propanamido)tetrahydro-2H-pyran-
2,4,5-triyl triacetate (39).  Compound 39 was synthesized using a procedure similar to 
compound 37, using 0.0536 g (0.077 mmol) of 13a  and 10.7 μL (0.11 mmol) of 3-
Bromopropionyl chloride to yield a brown precipitate that was vacuum filtered to give pure 39 as 
a brown solid (0.013 g, 22 %):  mp 140-144 oC. TLC (6:1 CHCl3/MeOH) RF = 0.67.  1H NMR 
data (D6-DMSO): δ 9.98 (s, 3H), 9.92 (s, 3H),  8.35 (t, J = 5.6 Hz, 1H), 7.83 (d, J = 9.2 Hz, 1H), 
7.22 (s, 1H), 7.17 (s, 1H), 6.89 (s, 2H), 5.75 (d, J = 8.8 Hz, 1H), 5.24 (t, J = 9.6 Hz, 1H), 4.85 (t, 
J = 9.6 Hz, 1H), 4.17 (dd, J = 4.8 Hz, 8 Hz, 2H), 3.98 (m, 3H), 3.82 (s, 3H), 3.76 (s, 3H), 2.05 (s, 
3H), 1.99 (s, 3H), 1.94 (s, 3H), 1.93 (s, 3H).  13C NMR (D6-DMSO): δ 170.50, 170.27, 170.10, 
169.73, 169.44, 166.83, 166.61, 162.01, 158.81, 123.24,122.83, 122.58, 122.13, 118.71, 118.64, 
104.97, 104.47, 92.19, 72.29, 71.98, 68.73, 61.95, 52.02, 43.08, 36.59, 36.44, 30.17, 21.04, 
20.96, 20.88, 20.86. 
(E)-2,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-N-(4-methoxybenzylidene)tetrahydro-
2H-pyran-3-amine (40).  Compound 40 was synthesized as described in literature.  A mixture of 
10 (0.787 g, 2.6 mmol) and benzyl bromide (2.53 mL, 21.1 mmol) in dry DMF (6 mL) was 
stirred vigorously in an ice/salt bath while NaH (57-63 % in oil, 0.887 g, 36.9 mmol) was added 
in four portions.  The mixture was then allowed to reach room temperature overnight.  EtOAc 
(50 mL) was added drop wise while stirring and then the solvent was removed by rotary 
evaporation.  The residue was taken up in EtOAc (50 mL) and DI H2O (50 mL), the organic 
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layer was separated, dried with MgSO4, and the solvent removed by rotary evaporation.  The 
compound was then dry loaded onto a column by dissolving the residue in EtOAc and adding 
about 5 g of SiO2 gel, then removing the solvent by rotary evaporation to give a solid.  Flash 
column chromatography of the solid (4:1 Hexane/EtOAc) afforded 0.870 g (50 %) of a yellow 
oil.  TLC (4:1 EtOAc/Hexane) Rf  = 0.29.  The NMR obtained was not well resolved to identify 
each peak due to the large number of phenyl groups present on the molecule, the ranges of 
signals were: 1H NMR data (D6-DMSO): δ 8.33 (s, 1H), 7.75 (d, J = 8.8 Hz, 2H), 7.42 – 7.14 
(phenyl, 30H), 7.0 (d, J = 8.8 Hz, 2H), 4.92 – 4.59 (10H), 3.93 (s, 3H).  13C NMR (D6-DMSO): 
δ 186.03, 133.64, 133.38, 133.12, 127.24, 125.27, 123.61, 123.57, 123.50, 12.36, 123.23, 12.11, 
123.01, 122.84, 122.72, 122.34, 109.58, 93.85, 73.50, 69.07, 67.63, 66.19, 64.10, 50.84. 
2-Amino-1,3,4,6-tetra-O-2deoxy-β-D-glucose Hydrochloride (41).  Compound 40 
(0.870 g, 1.32 mmol) was dissolved in acetone (10 mL), treated with HCl (5N, 1.5 mL), refluxed 
for 30 minutes, and then refrigerated overnight after having cooled to room temperature.  The 
white mass was broken, filtered using vacuum filtration, washed with acetone, and recrystallized 
with 190 proof EtOH to yield 41 (0.52 g, 68 %) as white crystals: mp decomposition 200 oC.  
The NMR obtained was not well resolved to identify each peak due to the large number of 
phenyl groups present on the molecule, the ranges of signals were: 1H NMR data (D6-DMSO): δ  
8.20 (s, 3H), 7.47 -7.15 (phenyl groups), 4.85 - 4.51, 3.71 -3.04.   13C NMR (D6-DMSO): δ 
138.61, 138.54, 138.19, 137.45, 128.76, 128.69, 128.64, 128.56, 128.28, 128.20, 128.15, 128.10, 
127.99, 127.97, 98.99, 80.15, 78.72, 74.81, 74.40, 74.16, 72.84, 71.02, 68.73, 55.24. 
4-Acrylamido-1-methyl-N-(1-methyl-5-(3-oxo-3(2,4,5-tris(benzyloxy)-6-
(benzyloxymethyl)tetrahydro-2H-pyran-3-ylamino)propylcarbamoyl)-1H-pyrrol-3-yl)-1H-
pyrrole-2-carboxamide (42).  In a flask flushed with N2, 15b (0.103 g, 0.26 mmol) was 
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dissolved in 4 mL of anhydrous DMF along with EDCI (0.105 g, 2.0 eq.), DMAP (0.106 g, 3.5 
eq.), HOBT (0.105 g, 3.0 eq,), CuCl2 (0.009 g, 0.3 eq.) and the amine hydrochloride 41 (0.152 g, 
0.26 mmol) was added and the solution was allowed to stir at room temperature over a period of 
two days.  The solution was diluted with 50 mL DCM and the organic layer extracted with H2O 
(2 x, 50 mL), 5 % NaHCO3 (2 x, 50 mL), and 1M HCl (2 x, 50 mL).  The organic layer was then 
dried over MgSO4.  The resulting solution was rotary evaporated until dry to yield the crude 
product, 16a which was purified using flash column chromatography (6:1 CHCl3/MeOH) as pale 
yellow solid ( 0.150 g, 62 %): mp 50-55 oC. TLC (6:1 CHCl3/MeOH) Rf  = 0.67.  The NMR 
obtained was not well resolved to identify each peak due to the large number of phenyl groups 
present on the molecule, the ranges of signals were:  1H NMR (D6-DMSO): δ  10.08 (s, 1H), 9.6 
(s, 1H), 8.0 (m, 3H), 7.36- 7.17 (m), 6.9 (s, 1H), 6.83 (d, J = 1.2 Hz, 1H), 6.36 (m, 1H), 6.19 (dd, 
J = 1.6 Hz, 1H),  5.64 (dd, J = 2 Hz,  1H), 4.8-4.49 (m).  13C NMR (D6-DMSO): δ 142.32, 
162.15, 161.79, 158.80, 138.80, 138.70, 138.37, 132.08, 128.73, 128.69, 128.66, 128.60, 128.33, 
128.21, 128.04, 127.91, 127.75, 125.86, 123.50, 123.24, 122.22, 118.49, 104.56,  
3-(1-Methyl-5-(1-methyl-5-(3-oxo-3(2,4,5-tris(benzyloxy)-6-
(benzyloxymethyl)tetrahydro-2H-pyran-3-ylamino)propylcarbamoyl)-1H-pyrrol-3-
ylcarbamoyl)-1H-pyrrol-3-ylamino)-3-oxopropane-1-sulfonic acid (43).  To a solution of 
alkene 42 (47.7 mg, 0.052 mmol) dissolved in 12 mL EtOH, NaHSO3 (0.105 g, 1 mmol) 
dissolved in 4 mL of DI H2O was added all at once.  The pH was adjusted to 8 with 5 % NaOH 
and the mixture was refluxed until 42 had disappeared and a baseline spot appeared by TLC (6:1 
CHCl3/MeOH).  The EtOH was then removed by rotary evaporation until a minimal amount of 
water remained.  This solution was then cooled in an ice/water bath and the pH adjusted to 1 
with concentrated HCl.  A pale yellow precipitate fell out of solution, which was vacuum filtered 
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to give pure 43 as a pale yellow solid (0.04 g, 77 %): mp 116-120oC. TLC (2:1 EtOAc/MeOH) 
Rf = 0.48.  The NMR obtained was not well resolved to identify each peak due to the large 
number of phenyl groups present on the molecule, the ranges of signals were: 1H NMR data (D6-
DMSO): δ 10.08 (s, 1H), 9.6 (s, 1H), 8.0 (m, 3H), 7.36- 7.17 (m).   
1-Methyl-4-(1-methyl-4-(3-(methylsulfonyl)propananmide)-1H-pyrrole-2-
carboxamid)-N-(3-oxo-3-[(2R,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydromthyl)tetrahydro-
2H-pyran-3-ylamino)propyl)-1H-pyrrole-2-carboxamide (44).  Compound 18b (0.052 g, 
0.065 mmol) was dissolved in 1.5 mL of anhydrous THF and cooled to – 10 oC in a dry 
ice/acetone bath.  Freshly prepared NaOCH3/MeOH (1M, 261 μL, 0.26 mmol) was added to the 
cooled solution.  The reaction was monitored by TLC (6:1 CHCl3/MeOH) initially until all spots 
collapsed to a baseline spot then TLC solvent was switched to MeOH and reaction was 
monitored until one spot was indicated by TLC, approx. 15 minutes.  Once complete by TLC 
Dowex 50-WA acidic resin was added to the cooled solution while stirring for 10 minutes.  The 
Dowex was filtered and washed with 1:1 DI H2O/MeOH.  The solvent was removed by rotary 
evaportation to give pure 44 as a brown solid (0.04 g, 97 %, mix of diastereomers): mp 172-180 
oC.  TLC (MeOH) Rf = 0.62. 1H NMR data (D6-DMSO): δ 10.06 (s, 1H), 9.87 (s, 1H), 7.97 (t, J 
= 4.8 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 9.6 Hz, 1H), 7.17 (dd, J = 4 Hz, 5.6 Hz, 2H), 
6.85 (d, J = 1.6 Hz, 2H), 6.42 (s, 1H), 4.93 (d, J = 3.2 Hz, 1H), 4.45 (d, J = 4 Hz, 1H), 3.82 (s, 
1H), 3.79 (s, 1H), 3.01 (s, 1H), 2.72 (t, J = 9.2 Hz, 2H).  13C NMR (D6-DMSO): δ 171.22, 
166.55, 161.65, 158.75, 123.26, 122.15, 118.63, 118.34, 104.54, 104.29, 91.04, 72.55, 71.58, 
70.92, 54.70, 50.20, 36.62, 36.43, 35.85, 28.65. 
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CHAPTER 6: RESULTS AND DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 The goals of this project were to develop compounds that can deliver a specific DNA-
methylating agent to pancreatic β-cells and that can be used to study the structural features that 
govern selective cell-targeting and DNA-damage.  These compounds will be used to demonstrate 
that a molecules that can form cytotoxic N3-methyladenine DNA-adducts exclusively can be 
directed to a particular cell-type by attaching it to targeting ligand and that this strategy can be 
used to destroy the targeting cell. 
 This thesis describes the synthesis of three categories of compounds for this project 
(Figure 6.1).  All three categories of compounds included a glucose unit at one end for achieving 
selective targeting of the pancreatic β-cells via the GLUT-2 glucose transporter.  They also 
contain a bis-pyrrole triamide unit that can achieve site-specific DNA-binding in the minor 
groove of DNA at A/T rich regions.  The difference between the three categories lies at the N-
terminus of these peptide molecules.  One set of compounds have fluorescent tags at this 
terminus and are designed for use in experiments to characterize cell-transport.  Another set of 
compounds bear a methyl sulfone unit at the N-terminus and will be used to characterize the 
DNA-binding properties of this class of compounds.  Finally, the third category of compounds 
have a reactive methyl-sulfonate at the N-terminus.  These compounds will be used to form the 
cytotoxic N3-methyl adenine DNA-adducts in pancreatic β-cells. 
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Figure 6.1: Structure of compounds being synthesized for this project. 
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The only variable in all of these compounds is the length of the linker unit.  In each of the 
categories, compounds were synthesized with three linkers each differing by 1 CH2 unit.  The 
compounds, differing in linker length, would help to explain how linker length influences DNA-
binding and transport through the glucose transporter. 
The synthetic schemes used for preparing the different compounds were similar and 
varied only in the sequence in which different components were added to compound 5 (Figure 
6.2).  Compound 5 has incorporated into it the bis-pyrrole unit that binds to DNA in the minor 
groove at A/T rich regions and the linker unit terminating as an ethyl ester.  The nitro group in 
compound 5 was reduced to an amine and then further functionalized with either the methyl 
sulfonate, methyl sulfone or fluorescent molecules as desired.  The terminal ester on compound 5 
was hydrolyzed and attached to the targeting ligand glucose.  
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Figure 6.2: Structure of compound 5. 
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The synthesis of compound 44b has been accomplished by the following procedure 
shown in Scheme 6.1.  Following this same scheme, compound 18a and 18c have also been 
successfully prepared and only require the deprotection of the hydroxyl groups on the glucose 
unit in order to convert them to the desired compounds.  These compounds will be used in 
binding studies to characterize their DNA-binding properties.   
 
Scheme 6.1 
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The synthesis of the compounds desired for the cell transport studies was carried out be 
the following steps outlined in Scheme 6.2.  Using this procedure compound 21 has been 
synthesized.  The deprotection of the glucose hydroxyl groups will result in the desired 
compounds containing fluorescent tags, which will be sent to collaborators in order to determine 
their selective transport through the GLUT-2 transporter.    
 
Scheme 6.2 
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For the synthesis of the desired DNA-methylating methyl sulfonate, compound 5 was 
first converted to compound 15, Scheme 6.3.  To this compound was attached the targeting 
ligand with the hydroxyl groups protected with benzyl groups or with acetyl groups.  Compound 
16 with the acetyl protected glucose was converted into the sulfonate salt, but the acidification of 
this sulfonate to the sulfonic acid resulted in partial deprotection of the glucose unit.  Efforts are 
ongoing to successfully achieve this transformation.  The benzyl protected compound has been 
successfully converted into the sulfonic acid, 43.  The removal of the benzyl protecting groups 
by hydrogenation has proved to be very sensitive to the catalyst used for the reaction, and 
different catalysts are currently being explored to achieve efficient deprotection.  Once the 
sulfonic acid compounds with the deprotected glucose unit are obtained, the final step required to 
make the desired methyl sulfonate compounds is the methylation of the sulfonic acid. 
  
 
Scheme 6.3 
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The methyl sulfonate compounds, once prepared, will be first test for their ability to 
produce 3-MeA adducts upon reaction with genomic DNA by using HPLC methods.  The ability 
of the compounds to form the desired cytotoxic DNA adducts will depend critically upon their 
ability to bind within the minor groove of DNA at A/T rich regions.  Molecular dynamics 
simulations performed using one of the desired molecules (R = CH2) indicates that this 
compound will indeed be able to bind within the minor groove at A/T rich regions (Figure 6.3) 
and that glucose unit itself contributes to the binding by forming favorable hydrogen bonding 
interactions within the groove.  Furthermore, based upon the solubility properties of the methyl 
sulfone compound 44b, it is likely that these desired DNA-methylating compounds will be water 
soluble, which is a big advantage for use in biological systems. 
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Figure 6.3: Molecular Mechanics model of methyl sulfonate compound bound to minor groove 
of DNA at A/T rich regions. 
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Precursor compounds in all three categories have been synthesized with three different 
linkers each differing by 1 CH2 group.  The differences between the properties of these 
compounds varying in linker-length will be used to identify the optimum length required for 
DNA-binding, cell-transport, and overall cell-toxicity.  If desired, the strength of DNA-binding 
can be improved by introducing a third pyrrole unit into the molecule.  The decreased water 
solubility due to this third pyrrole is not expected to be critical since the glucose unit provides 
significant water solubility.   
In transport experiments, the presence of the fluorescent tags may interfere with the 
passage of the compounds through the GLUT-2 transporter.  This is one of the reasons why two 
different fluorescent tags are being explored.  If the fluorescently tagged compounds are unable 
to get into cells via the transporter, it does not necessarily imply that the methyl sulfonate 
compounds will be unable to traverse through these transporters.  However, if these compounds 
with the tags do selectively get into cells containing the GLUT-2 glucose transporter, then it is 
likely that the methyl sulfonate compounds too will be able to pass through these transporters. 
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APPENDIX 
Appendix A.  Compounds Synthesized. 
Compound 
Number Structure Yield 
1 
 
80 % 
2 
 
80 % 
3a 
 
100 %
3b 
 
94 % 
3c 
 
98 % 
4 
 
91 % 
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5a 
 
79 % 
5b 
 
94 % 
5c 
 
80 % 
6 
 
56 % 
7 
 
56 % 
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8 
 
83 % 
9a 
 
99 % 
9b 
 
98 % 
9c 
 
96 % 
10 
 
62 % 
11 
 
83 % 
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12 
 
91 % 
13a 
 
87 % 
13b 
 
77 % 
13c 
 
86 % 
14a 
 
97 % 
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14b N
N
NH
O
O
H
N
O
HN
O
O
C21H27N5O4
Mol. Wt.: 413.47  
88 % 
14c 
 
79 % 
15a 
 
72 % 
15b 
 
70 % 
15c 
N
N
NH
O
O
H
N
O
HN
OH
O
C19H23N5O5
Mol. Wt.: 401.42  
78 % 
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16a N
N
NH
O
O
H
N
O
HN
O
O
AcO
OAc
N
H
OAc
OAc
Chemical Formula: C31H38N6O13
Molecular Weight: 702.67  
85 % 
16b 
 
95% 
16c 
 
98% 
17 
 
30 % 
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18a 
 
46%, 
 
18b 
 
40% 
18c 
 
46 % 
19 
 
90 % 
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20 
N
O
N HN
O2N
O
NH
N
O
H
N
N
O
HN
C23H25N9O6
Mol. Wt.: 523.50  
37 % 
21a 
 
48 % 
21b 
 
68% 
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21c 
 
60% 
22 
 
95 % 
23 
 
81 % 
24 N
H
N
O
H
N
N
O
OHHO3S
O
C15H18N4O7SMol. Wt.: 398.39  
74 % 
25 
 
21 % 
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26 
 
55 % 
27 
O
O
HO
OH
N
H
OH
OH
C13H17NO6
Mol. Wt: 283.28  
91 % 
28 
 
28% 
29 
 
57 % 
30 
 
74 % 
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31 
 
80 % 
32 
 
88 % 
33 
 
87 % 
34 
 
64 % 
35a 
 
98 % 
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35b 
N
N
NHO
O
NH
O
H
N
O
AcO
OAc
N
H
OAc
OAc
O
Chemical Formula: C33H44N6O13
Molecular Weight: 732.73  
87 % 
36 
 
24 % 
37 
 
84 % 
38 
 
94 % 
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39 
 
22  % 
40 
O
BnO
BnO
N
OBn
OBn
OCH3
Chemical Formula: C42H43NO6
Molecular Weight: 657.79  
50 % 
41 
 
68 % 
42 
 
62 % 
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43 
 
77 % 
44 
 
97 % 
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Appendix B. List of Abbreviation 
3-MeA - 3-methyladenine 
3-MeG - 3-methylguanine 
6-MeG - 6-methylguanine 
A – adenine 
Ac - acetyl 
A/T – adenine-thymine 
Bn - benzyl 
C – cytosine 
CDCl3 – Deuterated Chloroform 
DCM – dichloromethane 
DIEA –diisopropylethylamine 
DNA – deoxyribose nucleic acid 
DMAP – 4-dimethylaminopyridine 
DMF – dimethylformamide 
d6 -DMSO –Dimethylsulfoxide 
EDCI – 1-(3-dimethylaminopropyl)-3-ethylcarbodiimidehydrochloride  
EtOAc – ethyl acetate 
EtOH – ethanol 
G – guanine 
HCl – hydrochloric acid 
HOBT – hydroxybenotriazole 
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Me-lex – methyl 3-(1-methyl-5-(1-mehtyl-5-(propylcarbomyl)-1H-pyrrol-3-ylcarbamoyl)-1H-             
pyrrol-3-ylamino)-3oxopropane-1-sulfonate 
MeOH – methanol 
Mp – melting point 
NaOCH3 – sodium methoxide 
NaOH –sodium hydroxide 
NMR – nuclear magnetic resonance 
Pd/C – palladium on carbon 
Rf – retention factor 
TEA – triethylamine 
THF – tetrahydrofuran 
TLC – thin layer chromatography 
T - thymine 
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